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ABSTRACT 
Proteases from the Ovarian Tumor domain (OTU) superfamily of 
deubiquitinating enzymes (DUBs) are expressed by a range of RNA viruses.   Viral 
OTUs (vOTUs) are found in nairoviruses such as Crimean Congo Hemorrhagic Fever 
virus (CCHFV), Nairobi sheep disease virus (NSDV), the Erve virus (ERVEV), and the 
Dugbe virus (DUGV), as well as in the areterivirus Porcine Reproductive and Respiratory 
Syndrome virus (PRRSV), among others. vOTUs, which interfere with host innate 
immune response through editing of host Ub and Ub-like molecules such as interferon 
stimulated gene 15 (ISG15), have been identified as a potential virulence factor through 
their role in evading the innate immune response.  Study and characterization of vOTUs 
involves evaluating their activity and preferences for Ub, ISG15, as well as the variety of 
poly-Ub linkages that can form. While previous studies have compared vOTUs among 
different viruses, it was not known how vOTUs from differing strains of the same virus 
vary. To investigate vOTUs from differing strains of the same virus, vOTUs from two 
strains of PRRSV were selected.  The vOTU of a highly pathogenic PRRSV strain, 
JXwn06, and a strain used in vaccination, MLV, were enzymatically characterized.  
Intriguingly, the JXwn06 vOTU displayed a strong preference for K63 linked di-Ub, with 
over 40-fold greater activity than the MLV vOTU.  Additionally, neither strain showed 
significant activity towards ISG15, which is intriguing, as, at one point, it was believed 
 iii 
that deISGylating activity was a property of all vOTUs.  In contrast to these PRRS 
vOTUs, a strong deISGylating enzyme, the ERVE vOTU, was selected for enzymatic and 
structural investigation.  ERVE vOTU was found to not only prefer ISG15 over Ub, but 
recognized both mouse and human ISG15.  In order to gain insight into this ability to 
recognize more than one species of ISG15, the X-ray crystal structure of the ERVE 
vOTU in complex with the C-terminal domain of mouse ISG15 (CmISG15) was 
elucidated to 2.47 Å.  This structure not only revealed the structural configuration of the 
ERVE vOTU in complex with its substrate, but also provides the first structural 
information for mISG15.  Key areas of binding were identified upon comparison of the 
manner in which ERVE vOTU recognizes the mouse analog of ISG15 with CCHF vOTU 
substrate binding.  These key regions were explored through site-directed mutagenesis to 
determine if mutation at key binding areas would allow CCHF vOTU to more tightly 
bind mISG15. Based on CCHF vOTUs apparent lack of recognition of mISG15, special 
ISG15 constructs were designed to allow for testing against a panel of ISG15s from 
varying species. 
In another area of interest, adenylosuccinate lyase (ADSL) was structurally and 
enzymatically investigated to build understanding of ADSL deficiency, a rare autosomal 
recessive disorder, which causes a defect in purine metabolism resulting in neurological 
and physiological symptoms. To better understand the causation of disease due to 
the R303C mutation, the wild type (WT) and the R303C mutant of ADSL were 
investigated enzymatically and thermodynamically. Additionally, the X-ray structures 
of ADSL in its apo form as well as with the R303C mutation were elucidated, providing 
insight into ADSL’s cooperativity.  
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CHAPTER ONE: THE VOTU DOMAIN OF HIGHLY-PATHOGENIC PORCINE 
REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS DISPLAYS A 
DIFFERENTIAL SUBSTRATE PREFERENCE 
Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a rapidly 
evolving virus which emerged as a serious pathogen of swine in the late 1980’s, and has 
since become one of the most significant concerns to the global pork industry. These 
concerns have only been exacerbated by the emergence in 2006/2007 of highly 
pathogenic PRRSV (HP-PRRSV) in China and Southeast Asia (Li et al. 2007, Wu et al. 
2009, Guo, Lager, Henningson, et al. 2013). More contemporary PRRSV isolates have 
been observed in Southeast Asia that show significant continuing evolution from the 
original 2006 isolates, but still retain the highly pathogenic phenotype (Yu et al. 2012, 
Guo, Lager, Schlink, et al. 2013).  These observations underscore the need to 
mechanistically understand what is responsible for the increased virulence of HP-
PRRSV, which is further complicated by the complex and poorly understood virulence 
determinants of the broad and genetically diverse PRRSV strains. 
Upon infection with PRRSV, viremia is typically established in 6-12 hours and 
virus shedding has been observed for up to 157 days (Wills et al. 1997). It is likely that 
the prolonged time to virus clearance is directly related to the immunosuppressive effects 
of PRRSV infection. Although the mechanisms through which PRRSV subverts the 
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adaptive immune response have been mostly determined (Sang, Rowland, and Blecha 
2011, Yoo et al. 2010, Charerntantanakul, Platt, and Roth 2006), the manner in which 
some strains of PRRSV initiate a comprehensive campaign against the innate immune 
response have not. Specifically, mechanism behind the apparent dysregulation of several 
innate immune pathways such as the type I interferon/IRF/NF-κB mediated innate 
immune pathways in cultured cells (Sun et al. 2010, Sun, Han, et al. 2012, Fang et al. 
2012, Beura et al. 2010, Song, Krell, and Yoo 2010, van Kasteren et al. 2013), have 
remained elusive.   
PRRSV is a positive-sense, single-stranded RNA virus in the genus Arterivirus of 
the family Arteriviridae. Phylogenetic analysis of PRRSV reveals two genetically distinct 
genotypes: Type 1/European PRRSV (type strain Lelystad) and Type 2/North American 
PRRSV (type strain VR-2332), with the HP-PRRSV isolates belonging to a distinct 
subgroup of Type 2. It is important to note, however, that due to a high rate of mutation 
and recombination, it is likely that actual genetic diversity of PRRSV continuously surges 
ahead of our ability to discover and characterize it (Shi et al. 2010).  The PRRSV genome 
is 15 to 15.5 kb, and contains at least 10 open reading frames (ORFs), with 12 non-
structural proteins (nsp) (Chand, Trible, and Rowland 2012).  Due to the high degree of 
variability in nsp2, it remains likely that functional differences exist in nsp2 between 
various PRRSV isolates that might have consequences on strain virulence.  
PRRSV nsp2 is a large, highly variable protein encoded in the ORF1a region of 
the genome as part of a larger polyprotein precursor (Snijder et al. 1995, Han, Wang, and 
Faaberg 2006, van Hemert and Snijder 2008).  Nsp2 is liberated from this precursor via 
cleavage of the nsp1β:nsp2 junction by the nsp1β protease and cleavage of the nsp2:nsp3 
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junction by the intrinsic protease activity of nsp2 (den Boon et al. 1995, Snijder et al. 
1995, van Hemert and Snijder 2008, Han, Rutherford, and Faaberg 2009).  This protease 
activity resides within an amino-terminal region of nsp2 containing a papain-like cysteine 
protease domain (PLP2) that cleaves at a conserved GG dipeptide between nsp2 and nsp3 
(Han et al. 2009, Ziebuhr, Snijder, and Gorbalenya 2000, Mielech et al.).  It has also been 
shown bioinformatically that this PLP2 domain is part of a larger family of mammalian 
proteins known as the ovarian tumor domain (OTU) proteases (Frias-Staheli et al. 2007).  
This subgroup of viral OTU domains (vOTU) have been biochemically shown to act as 
deubiquitinases (DUB) of varying specificities and activities, capable of interfering with 
innate immune responses via dysregulation of ubiquitin (Ub) or ISG15 related protein 
signaling (Frias-Staheli et al. 2007, Capodagli et al. 2011, Akutsu et al. 2011, Capodagli 
et al. 2013). 
Ub is involved in a number of cell signaling pathways through attachment to host 
protiens in a variety of linkages of poly-Ub chains. These poly-Ub chains form via an 
isopetide bond between the C-terminus of one Ub with either the N-terminus, or one of 
seven other lysine residues, of another Ub molecule.  Both mono- and polyubiquitination 
of host proteins act as key regulatory steps in multiple distinct cell signaling pathways 
(Komander, Clague, and Urbe 2009, Kulathu and Komander 2012).  One relevant 
example of this is the use of K63-linked poly-Ub in the activation of retinoic acid-
inducible gene I/mitochondrial antiviral signaling protein (RIG-I/MAVS) (Zeng et al. 
2010), linear poly-Ub-dependent activation of inhibitors (IκB kinases) of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) (Tokunaga et al. 2009), and 
K48-linked poly-Ub to trigger degradation of IκB and activation of NF-κB signaling 
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(Chen et al. 1995, Alkalay et al. 1995).  Alternative forms of ubiquitination (K6, K11, 
K27, K33) have been implicated in other cellular functions, including lysosome/vesicle 
trafficking, DNA damage response, inhibition of protein degradation, mitochondrial 
damage/autophagy, endoplasmic reticulum (ER) associated protein degradation, T-cell 
activation, and tumor necrosis factor-alpha (TNFα) signaling (Kulathu and Komander 
2012).  Further, there exist multiple Ub-like proteins, such as interferon (IFN) stimulated 
gene 15 (ISG15), for which there are diverse functions and regulatory pathways including 
anti-viral host defense (Zhao et al. 2013).  It is clear from this diverse and interwoven set 
of processes that it is insufficient to simply define a protease as a vOTU or DUB and 
subsequently ascertain the global picture of downstream cellular effects. 
Herein, we describe detailed biochemical characterization of the vOTU activity of 
the PLP2 domain from a HP-PRRSV strain (JXwn06), and contrast that activity to that 
from the PLP2 domain of the avirulent modified live virus vaccine strain Ingelvac 
PRRS® (MLV).  To do this, we utilized purified vOTU domains in an in vitro activity 
assay with chemically defined, purified substrates.  This system provides significant 
advantages to in cellulo and in vivo activity assays, including the ability to directly query 
substrate preference and observe simplified reaction kinetics.  Further, these assays avoid 
complications due to off-target effects or effects on complex cellular pathways which can 
make data interpretation problematic.  Using this approach, we demonstrate that both the 
MLV and JXwn06 vOTU/PLP2 domains showed DUB activity on K48-Ub and K63-Ub 
substrates.  Interestingly, the PLP2 domain from HP-PRRSV strain JXwn06 displayed 
significantly greater activity against K63-Ub substrates than the PLP2 domain of MLV.  
This represents the first report of a biochemical activity unique to HP-PRRSV that has 
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potential implications for increased immunosuppression and may contribute to the 
increased virulence exhibited by this Asian HP-PRRSV strain. 
Experimental Procedures 
Construction of OTU Domains and Porcine proISG15 
Ingelvac PRRS® nsp2 nucleotides 1342-1986, coding for nsp2 aa 1-215, were 
inserted downstream of a 6x histidine tag, codon optimized for expression in E. coli, and 
used to synthesize the viral OTU polypeptide (MLV vOTU) (GenScript, Piscataway, NJ). 
A JXwn06 vOTU polypeptide representing nsp2 aa 1-215 was produced in a like manner.  
The coding sequence for porcine proISG15 (NM_0011286469) was codon optimized for 
expression in E. coli, and internal restriction endonuclease recognition sequences were 
altered by silent mutagenesis for cloning purposes (Huang et al. 2009).  This optimized 
gene was synthesized with an amino terminal 3X FLAG-Tag and 10X His-Tag, as well as 
NcoI and BamHI sites for cloning purposes at the 5’ and 3’ ends, respectively 
(GenScript).  This synthetic gene was subcloned into pET26b (EMD Millipore) for 
bacterial expression and purification. 
Protein Purification 
Porcine proISG15 (pproISG15) was purified from E. coli BL21(DE3) cells 
harboring the gene for pproISG15 grown at 37 ˚C in 6 L of LB broth containing 100 
µg/mL of ampicillin until the optical density at 600 nm reached 0.6. Expression of 
pproISG15 was induced by the addition of IPTG to a final concentration of 0.5 mM at 20 
˚C overnight. The cells were resuspended in cold Buffer A (50 mM Tris [pH 7.5], 1 mM 
EDTA, and 20% (w/v) sucrose), and then centrifuged at 6700 x g for 30 minutes. The 
cells were then resuspended in 5 mM MgCl2. The suspension was centrifuged at 6700 x g 
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for 30 minutes, and the protein was purified from the supernatant via Ni-NTA affinity, 
followed by size-exclusion chromatography on a Superdex75 using Buffer B (200 mM 
NaCl, 20 mM HEPES [pH 7.5], 2 mM DTT). The protein was further purified by cation 
exchange using a 10/100 MonoS column. The protein was eluted using a gradient from 
Buffer C (100 mM NaCl, 50 mM ammonium acetate [pH 4.5]) to Buffer D (1000 mM 
NaCl, 50 mM ammonium acetate [pH 4.5]). The vOTU from Crimean Congo 
hemorrhagic fever (CCHFV vOTU) was purified as described previously (Capodagli et 
al. 2011). 
Fluorescent vOTU Deubiquitination and DeISGylation Assays 
All assays were performed in duplicate in Buffer E (100 mM NaCl, 50 mM 
HEPES [pH 7.5], 0.01 mg/mL bovine serum albumin (BSA), 5 mM DTT) using a 
Corning Costar half-volume black 96-well plate with a reaction volume of 50 µL. The 
rates of the reactions were observed using an Infinite M1000 series plate reader (Tecan, 
Inc.). Specifically, the increase in fluorescence (excitation λ, 360 nm; emission, 460 nm) 
of 7-amino-4-methylcourmarin (AMC) upon cleavage from hUb-AMC, hISG15-AMC, 
(Boston Biochem, MA) and ZRLRGG-AMC (Bachem) substrates was monitored for 
JXwn06 and MLV vOTU (GenScript). To calculate turnover rates for 1 µM hISG15-
AMC, 1 µM hUb-AMC, and 50 µM ZRLRGG-AMC, 1 µM, 4 nM, and 4 µM of enzyme 
were used against hISG15-AMC, hUb-AMC, and ZRLRGG-AMC, respectively.  
The turnover rates for poly-Ub fluorescence resonance energy transfer (FRET) 
linkage substrates K11, K48, and K63 (Boston Biochem, MA) were determined by 
monitoring the increase in fluorescence (excitation λ, 544 nm; emission, 572 nm) 
resulting by the separation of a FRET TAMRA/QXL pair. Cleavage of three 
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commercially available FRET TAMRA/QXL pair configurations per K48 and K63 poly-
Ub linkage FRET substrates were assessed. Each di-Ub FRET substrate at 1 µM was 
evaluated against an enzyme concentration of 500 nM.  
Gel Shift Assays 
Poly-Ub linked by the different isopeptide bonds (K6, K11, K29, K33, K48, and 
K63), as well as the N-terminal peptide bond (linear), were purchased from Boston 
Biochem, MA. K27 linked di-Ub was purchased from Ubiquigent. Dimeric-Ub substrates 
(10 µM) were incubated with 500 nM JXwn06 or MLV vOTU in reaction Buffer F (100 
mM NaCl, 50 mM HEPES [pH 7.5], and 2 mM DTT) at 37 ˚C. Reactions were stopped at 
various times over 1 hour by mixing 9 µL of each reaction with 2 × SDS-Tricine sample 
buffer and heating at 95 ºC for 5 minutes. Results were visualized on 10 – 20% Mini-
PROTEAN® Tris-Tricine Precast Gels (Bio-Rad, CA). For vOTU cleavage of trimeric 
K48 and K63 linkages, 20 µM of tri-Ub substrates were tested and analyzed in the same 
manner as di-Ub. 
10 µM hproISG15, (Boston Biochem, MA) was incubated at 37 ˚C with 20 nM 
CCHFV vOTU, 14 µM  MLV, or 20 µM JXwn06 vOTU. 10 µM pproISG15 was 
incubated at 37 ˚C with 20 nM CCHFV vOTUs. ProISG15 gel shift assays were tested 
and analyzed in the same manner as di-Ub. The concentrations of MLV and JXwn06 
used were the maximum allowable concentration possible for this assay. 
Assay for vOTU Cleavage of Porcine proISG15 by Anti-FLAG® Western Blotting. 
The pproISG15 cleavage assays were assembled as described above in reaction 
buffer F, containing 10 µM pproISG15, and either 100 nM CCHFV vOTU or 1000 nM 
PRRSV vOTU domain.  Reactions were incubated at 37 ºC, and aliquots were removed at 
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time 0, 1, 2, 5, 10, 30, and 60 minutes, as well as at 24 hours.  Reaction progress was 
halted by addition of the removed aliquots to an equal volume of SDS-PAGE loading 
buffer and storage at -20 ºC until electrophoresis. 
Timepoint samples for pproISG15 cleavage assays were separated by 10% 
Tris-Tricine SDS-PAGE, and resolved proteins were transferred to a PVDF membrane 
using the iBlot transfer apparatus (Life Technologies).  The membrane was blocked with 
3% milk in PBS and immunoblotted with a 1:3000 dilution of mouse α-FLAG® 
monoclonal antibody (Sigma-Aldrich; F1804).  Proteins were detected using a 1:15000 
dilution of peroxidase conjugated goat α-mouse IgG antibody (Zymax, Life 
Technologies) and the ECL Plus substrate (Pierce).  Immunoblots were visualized using 
blue light fluorescence in a G:BOX imager (Syngene). 
Results 
Sequence Comparison of PRRSV strain JXwn06 and MLV vOTU domains 
The vOTU domains of very few strains of PRRSV have been directly examined 
for suppression of innate immunity in cell culture.  Two such studies utilized SD01-08 (a 
Type 1 isolate) (Sun et al. 2010) or VR-2332 (van Kasteren et al. 2012), which both 
cause only mild disease in vivo, and neither of which included an assessment of enzyme 
kinetics. Another study examined the ability of HP-PRRSV strain 07HBEZ vOTU to 
suppress IFN-β induction in vitro (Li et al. 2010).  To more precisely examine and 
compare vOTU domain enzymatic activity and specificity for PRRSV strains of differing 
pathogenicity, the vaccine derivative, Ingelvac PRRS® MLV and HP-PRRSV strain 
JXwn06 were chosen for analysis. A vOTU domain alignment of these two PRRSV 
strains compared to a related arterivirus (equine arteritis virus; EAV) and CCHFV was 
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produced, using the catalytic and zinc-binding residues as alignment signature amino 
acids (Fig. 1). The two PRRSV strains display 83.7% identity/84.2% similarity within the 
designated vOTU region, while this domain displays ~21% identity between both 
PRRSV strains and EAV, and only ~10% identity between PRRSV and CCHFV.  
Characterization of Strain Specificity 
In order to investigate potential functional differences between vOTU domains 
from different PRRSV strains, we obtained biochemical data on the activity and 
specificity of PRRSV vOTU domains from strains JXwn06 and MLV. Initially, 
enzymatic activity was assessed utilizing Ub and ISG15 substrates, as well as a peptide 
substrate comprised of the five C-terminal amino acids common to Ub and ISG15, 
RLRGG (Fig. 2). By monitoring the release of the aminomethylcoumarin fluorophore 
from the C-terminus of these substrates, rate and substrate preference data was obtained.  
The vOTU domains originating from JXwn06 and MLV possess a noteworthy ability to 
cleave human Ub-AMC (hUb-AMC) conjugates, at 3.67 ± 0.04 and 2.30 ± 0.04 min-1, 
respectively.  However, when these vOTUs were assessed for activity against human 
Figure 1: Sequence alignment of vOTUs. Sequence similarity is indicated as non-conserved (white 
background, black text), similar (yellow background, black text), conserved (green background, white 
text), or all matching (dark green background, orange text). Catalytic residues are boxed in red, and zinc-
binding residues are boxed in purple.  PRRSV sequence numbering is based on the residue number 
within nsp2. 
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ISG15-AMC (hISG15-AMC), the vOTUs of JXwn06 and MLV exhibited activity 2,500 
and 320 times less than their activities toward Ub-AMC, respectively.  Interestingly, 
when assessed using the peptide substrate ZRLRGG-AMC, which is comprised of the 
last five conserved amino acids between Ub and ISG15, a large deviation in activity was 
observed between the vOTUs from MLV and JXwn06. Specifically, the activity of the 
MLV vOTU was 0.40 ± 0.04 min-1, whereas JXwn06 vOTU was only 2.05 ± 0.01 x 10-2 
min-1. This result, as well as the dramatic difference between cleavage of Ub-AMC and 
hISG15-AMC, suggests a more complex interaction with the protein substrate beyond 
simple recognition of peptide sequence.  
Di-Ubiquitin Specificity Divergence 
In some cases, vOTU domains have been shown to have higher turnover rates for 
poly-Ub than for Ub-AMC due to an increase in the number of favorable contacts to 
which the enzyme can bind the substrate (Capodagli et al. 2013). Although the activity 
for mono-Ub was found to be relatively similar between JXwn06 and MLV vOTUs, 
Figure 2: Kinetic data for fluorescence based assay. JXwn06 
vOTU data is shown in gray and MLV vOTU data is shown in 
white. ISG15-AMC data is shown in the insert for clarity. 
Turnover number of substrate is measured as increase in 
fluorescence as AMC is cleaved off of the substrate molecule. 
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differences in rates of cleavage for di-Ub may exist between strains. To more precisely 
differentiate the di-Ub specificities of the JXwn06 and MLV vOTU domains, a panel of 
varying di-Ub substrates (composed of K6, 11, 27, 29, 33, 48, 63 and linear di-Ub 
linkages; Fig. 3a) was screened for activity. Both vOTU domains had an overall trend of 
Figure 3: Cleavage of di- and tri- Ub. (a) Cleavage of various di-Ub linkages by JXwn06 and MLV 
vOTUs. (b) Kinetic data for FRET based Di-Ub assay. JXwn06 vOTU data is shown in gray and 
MLV vOTU data is shown in white. (c) Cleavage of tri-Ub by JXwn06 vOTU and MLV vOTU. 
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highest activity towards K63 linked di-Ub, followed, in descending order, by K11, K29, 
K6, K27, and K48-linkage, with no detectable activity toward linear linked di-Ub. 
Interestingly, while the observed activity was similar for most di-Ub linkages, JXwn06 
vOTU was markedly more active toward K63 di-Ub, cleaving nearly all of the substrate 
within 10 min, compared to the MLV vOTU, for which a significant proportion of 
uncleaved K63 substrate remained after 60 min. In order to quantify the difference in 
activity towards di-Ub substrates, cleavage of K11, K48, and K63 di-Ub FRET substrates 
was assessed. These results aligned with the di-Ub gel shift assays, with both vOTU 
domains displaying low activity towards K48 linked di-Ub, and disparate activities 
utilizing K63 linked di-Ub. The activity of the JXwn06 vOTU towards K63 linked di-Ub 
was determined to be approximately 40-fold higher than that of MLV vOTU (Fig. 3b). 
To assess potential differences in vOTU domain activity on substrates similar to 
poly-Ub, activity assays were performed using K48 and K63 linked tri-Ub (Fig. 3c).  In 
stark contrast to the K48 linked di-Ub substrate, both vOTU domains of MLV and 
JXwn06 rapidly cleaved the majority of K48 tri-Ub into di- and mono-Ub within 5 min.  
However, consistent with the previous results, the resulting K48 linked di-Ub appeared 
refractory to subsequent vOTU cleavage.  As in the di-Ub cleavage assay, the K63 linked 
tri-Ub substrate was rapidly and completely cleaved to mono-Ub by the JXwn06 vOTU 
domain within 10 min. Unlike the surge in activity observed using K48 linked tri-Ub for 
the MLV vOTU domain, its cleavage of K63 linked tri-Ub proceeded at the same modest 
rate observed for K63 di-Ub. 
13 
Pro-ISG15 Activity 
While Ub is highly conserved among species, ISG15 is more divergent, with 
human and porcine ISG15 sharing 67% sequence homology. Nairovirus vOTUs such as 
the CCHFV vOTU have previously been demonstrated to possess species specificity for 
ISG15 (Capodagli et al. 2013). To determine if the low hISG15-AMC activity observed 
for JXwn06 and MLV vOTU domains was also related to species specificity, cleavage of 
the pro-form of human (hproISG15) and porcine (pproISG15) were examined, using the 
CCHFV vOTU as a control. First, cleavage of hproISG15 was examined. At the low 
enzyme concentration of 20 nM, CCHFV vOTU cleaved the hproISG15 at a rate that was 
readily observed in the one-hour time trial (Fig. 4a). Since the PRRSV vOTUs exhibited 
much lower turnover numbers for hISG15-AMC, the highest allowable concentrations of 
MLV and JXwn06 were utilized. However, even at the increased concentrations for MLV 
and JXwn06 vOTUs, no cleavage of the hproISG15 was observed for either in the one-
hour time span (Fig. 4a). When examining cleavage of pproISG15, while CCHFV vOTU 
was seen to cleave the pproISG15 at a significantly reduced rate to that of hproISG15, no 
cleavage of pproISG15 by JXwn06 and MLV vOTU domains was detected within a one-
hour time course. It was only after an extended 24-hour incubation that a trace of cleaved 
product was observed (Fig. 4a, b).   
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Discussion 
The identification of a vOTU domain in nsp2 of the arterivirus PRRSV sets it 
among a number of viruses containing vOTUs, including nairoviruses, tymoviruses, a 
tenuivirus, and other nidoviruses. Recently, vOTUs from nairovirus representatives 
CCHFV, Dugbe virus and Erve virus (ERVEV), as well as the tymovirus prototypical 
member turnip yellow mosaic virus (TYMV) were probed extensively, and illustrated 
Figure 4: ProISG15 gel shift assay. (a) Cleavage of human (h) proISG15 by CCHFV, JXwn06, or 
MLV vOTU is shown over a one-hour time course and visualized by coomasie blue staining. (b) 
Cleavage of porcine (p) proISG15 by varying concentrations of CCHFV, JXwn06 and MLV vOTUs 
are shown over a one hour time course as well as a 24-hour time point. Cleavage products were 
visualized by anti-FLAG® western blot of tagged-pproISG15. 
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vOTUs from different species can vary greatly in their preference for substrate 
(Capodagli et al. 2013).  The vOTUs from JXwn06 and MLV follow this trend. Relative 
to previously characterized vOTU domains of viruses, JXwn06 and MLV vOTU domains 
displayed moderate deubiquitinating activity. The vOTUs previously probed have 
deubiquitinating activity which ranges from approximately 0.03 to 27 min-1 (Capodagli et 
al. 2013). The PRRSV vOTUs fall into the lower end of this range, with deubiquitinating 
activity closest in value to that of ERVEV vOTU, which is considered a poor 
deubiquitinating enzyme relative to other nairoviruses (Capodagli et al. 2013). However, 
relative to nairovirus counterparts, such as vOTUs from CCHFV and ERVEV, that  
clearly possess deISGylating activity, PRRSV vOTUs deISGylating activity is extremely 
low. Comparatively, other vOTUs have activity ranging from ERVEV vOTU at the high 
end, at 15 min-1, to TYMV vOTU at the low end with activity of only 0.005 min-1. The 
PRRSV vOTUs hISG15 activities are near the lower end of these reported vOTU 
activities, with similar values to the TYMV vOTU, whose plant host lacks an ISG15 
homologue. Upon comparing the proteolytic activity of the PRRSV vOTUs toward the 
last five amino acids common to both Ub and ISG15 as measured by cleavage of 
ZRLRGG-AMC, a divergence in their comparative activities was found. The activity of 
the MLV vOTU is 20 times greater than that of the JXwn06 vOTU and 30% greater than 
the highest activity observed in the recent survey of representative vOTU domains 
reported by (Capodagli et al. 2013). 
Further comparison and analysis of the vOTU domain from the highly pathogenic 
JXwn06 strain of PRRSV with the vOTU domain of the less pathogenic North American 
MLV strain revealed an intriguing result. The less virulent MLV vOTU maintained a 
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better proteolytic activity, as measured by fold change of relative cleavage of ZRLRGG-
AMC, and the two vOTUs had similar moderate Ub-AMC activity.  However, upon 
examining the activity of the two strain’s vOTUs towards poly-linked Ub, rather than the 
mono-Ub-AMC, a large divergence in their activities was uncovered. The JXwn06 vOTU 
exhibited K63 linked Ub activity over 40 times greater than that of MLV, exemplifying 
how vOTUs with similar activity against mono-Ub may have divergent activity towards 
different di-Ub linkages.  Suppression of K63 linked poly-Ub early in infection by 
JXwn06 may contribute to the increased disease severity in highly pathogenic PRRSV 
infection.  
During initial examination of vOTU domains, such as that from CCHFV, it was 
theorized that all vOTUs might possess dual deubiquitinating and deISGylating activity. 
However, further work demonstrated that some vOTUs likely serve primarily as 
deubiquitinases, while others may have a stronger preference for ISGylated substrates 
(Capodagli et al. 2013). For PRRSV vOTU domains from Jxwn06 and MLV, both were 
found to not only have very low activity against hISG15-AMC, but were unable to 
appreciably cleave either pproISG15 or hproISG15. The latter experiment eliminates a 
species-specificity effect, as seen in CCHFV vOTU, as the primary driver for the absence 
of activity (Fig 4b,c).  As a result, the lack of deISGylating activity suggests that PRRSV 
core domain may be more suited as a deubiqutinase than a deISGylase.  The lack of 
deISGylating activity is surprising given that PRRSV nsp2 has been previously suggested 
to play a direct role in reducing the amount of ISGylation in cells (Sun et al. 2012). This 
may indicate additional protein requirements for cleavage of ISG15 by PRRSV vOTUs. 
These additional requirements may come in the form of accessory proteins, or in a 
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requirement for a larger domain within the nsp2 protein, as it has previously been 
demonstrated that larger proteolytically active domains of nsp2 were required for trans 
vs. cis cleavage specificities (Han, Rutherford, and Faaberg 2009).  Alternatively, the 
observed cleavage of ISG15 modified proteins in cell culture may be due to an upstream 
effect of nsp2, rather than a direct effect of vOTU domain activity. Also, the extended 
time course inherent in cellular testing, coupled with the observed trace activity of 
PRRSV vOTUs for ISGylated substrates, may have permitted the gradual buildup of 
deISGylated substrates thereby exaggerating the magnitude of PRRSV vOTU’s 
deISGylating activity. This is of particular importance, given the kinetics of the antiviral 
response, particularly in the early stages of viral infection. 
PRRSV virulence and attenuation have been studied extensively, with most 
studies implicating multiple regions of the virus in contributing to virulence, consistent 
with the observation that individual PRRSV vaccines appear to have become attenuated 
by different mechanisms (Brockmeier et al. 2012, Wang et al. 2008, Kwon et al. 2008, 
Storgaard, Oleksiewicz, and Botner 1999, Ni et al. 2013, Nielsen et al. 2001, An et al. 
2011, Shi et al. 2013, Ellingson et al. 2010, Yuan et al. 2001, Han et al. 2013, Kim et al. 
2010, Song, Krell, and Yoo 2010). Narrowing the focus to the PLP2/vOTU region of 
nsp2, previous reports have generally demonstrated deubiquitinating activity of certain 
strains, leading to subsequent suppression of innate immune responses in infected cells 
(Frias-Staheli et al. 2007, van Kasteren et al. 2012, Sun et al. 2010, Li et al. 2010), 
suggesting a mechanistic role in PRRSV virulence. In this report, we have shown that the 
core vOTU domain (215 residues), which varies only 17% (amino acid identity) between 
different strains of PRRSV, was responsible for marked differences in K63-linked 
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deubiquitination, reinforcing the role of the PLP2/vOTU domain in virulence variation 
between PRRSV strains. It is important to note that this core domain must function 
primarily as a viral protease, placing significant constraints on evolution of secondary 
functions. This also underscores the complexities of PRRSV virulence, since MLV and 
its parental field isolate (VR-2332) share the identical vOTU domain sequence while 
exhibiting differential pathogenicity in swine.  Therefore it is crucial to recognize that 
while differential vOTU activity may contribute to virulence, it remains one of a 
constellation of potential virulence factors.  Mechanistically, several critical innate 
immune sensors and cellular anti-viral pathways utilize K63 ubiquitination as an essential 
activation step, such as RIG-I/MAVS, MDA5, and MITA/STING (Oshiumi et al. 2013, 
Jiang et al. 2012, Guo, Lager, Schlink, et al. 2013).  Antagonism of these pathways by a 
vOTU domain with preference for K63-polyubiquitin could lead to a decrease in type I 
interferon production and NF-κB signaling, thereby abrogating or significantly delaying 
establishment of the anti-viral state.  If K63 preference and increased deubiquitination 
activity of the JXwn06 vOTU domain is a shared characteristic of all highly-pathogenic 
PRRSV isolates, then it is possible that this unique activity contributes to the increased 
virulence of these strains.
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CHAPTER TWO: IDENTIFYING FACTORS OF SPECIES PREFERENCE OF 
VOTUS FROM CCHFV AND ERVEV TOWARDS ISG15 
Introduction 
Nairoviruses are negative-sense single stranded RNA viruses, which infect both 
animals and humans.  The genus includes 34 known viruses, of which the Crimean-
Congo Hemorrhagic Virus (CCHFV), Dugbe Virus (DUGV), and Nairobi sheep virus 
(NSDV) have been the most investigated. The Erve nairovirus (ERVEV), which was 
isolated from the white-toothed shrew in 1982 in northwest Europe, has been implicated 
as a causative agent in human thunderclap headaches. Among nairoviruses, disease 
outcomes in humans can range from mild symptoms, such as headaches, as is the case 
with the Erve virus, to severe hemorrhaging, high fever and death with CCHFV 
(Capodagli et al. 2013).  
Intriguingly, while CCHFV is often fatal in humans, it shows no signs of disease 
in a large range of infected animals. Likewise, NSDV, which is fatal in sheep, only 
causes mild febrile illness in humans. The most recently identified nairovirus, the 
Leopards Hill virus (LPHV), causes severe disease in mice (Ishii et al. 2014). It is 
currently unknown why severe disease is presented to only a single species infected with 
these nairoviruses.  One key factor may lay in the ability of a nairovirus to efficiently 
circumvent the immune response of certain species. Recently, a potential nairovirus 
virulence factor, ovarian tumor domain protease (vOTU) found within the L-segment of 
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narioviruses’ genome, was identified. Investigations into vOTU‘s preference for ubiquitin 
(Ub) and Ub-like proteins have revealed differing specificities toward different host’s 
Ub-like interferon stimulated gene product 15 (ISG15). Specifically, the vOTU from 
CCHFV has been shown to be highly specific to human ISG15 (hISG15), while the 
vOTU from ERVEV can recognize both mouse and human ISG15.  In order to further 
understand this behavior, a complex of the ERVE vOTU with the C-terminal domain of 
mouse ISG15 (CmISG15) was elucidated to 2.47 Å. Additionally, constructs of ISG15s 
of varying species in a designed pro-form were paneled against varying vOTUs to probe 
the vOTUs species preferences further. 
Experimental Procedures 
vOTU and CmISG15 Construct Design 
For the ERVE vOTU expression construct, the first 171 amino acids from the L-
protein in ERVEV (GenBank AFH89032.1), and for the NSD vOTU, the first 186 amino 
acids from the L-protein in NSDV (GenBank AED88229.1), which both correspond to 
the first 169 amino acids of CCHF vOTU (Fig. 5) and include the OTU domain as 
described by Dilcher et al. (2012) were utilized. Similarly to the CCHF vOTU construct, 
six histidines and a stop codon were added to ERVE vOTU and NSD vOTU constructs to 
generate a C-terminal histidine tag. ERVE vOTU was incorporated into pET11a plasmids 
using NdeI and BamHI restriction sites, and NSD vOTU was incorporated into pET28a. 
Addgene plasmid 12448 harboring mouse ISG15 (mISG15) in pET15b (mISG15-
pET15b) as described in Kim and Zhang (2005) was obtained from Addgene. Cysteine 78 
of mISG15 was mutated to a serine as described in Sorensen et al. (2007). The C-terminal 
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domain of mISG15 (CmISG15) was amplified by PCR, and was then sub-cloned into 
pTYB2 using NdeI and SmaI restriction enzyme sites (CmISG15-pTYB2). A CmISG15 
Figure 5: Sequence alignment of ISG15s and of vOTUs. (a) The ISG15 from T. belangeri (Northern 
tree shrew), H. sapiens (human), O. aries (sheep), M. musculus (mouse) and O. faciatus (jackknife fish) 
are shown aligned.  The secondary structure of CmISG15 according to Defined Secondary Structure of 
Proteins (DSSP) is shown as blue cylinders (helices), blue arrows (beta sheets), and black lines (loops). 
(b) ERVE vOTU, NSD vOTU, CCHF vOTU, and DUG vOTU are shown aligned. The secondary 
structure of ERVE vOTU according to Defined Secondary Structure of Proteins (DSSP) is shown as tan 
cylinders (helices), tan arrows (beta sheets), and black lines (loops).  Dashed lines represent regions for 
which electron density was not defined in the crystal structure.  
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construct in pET15b (CmISG15-pET15b) was generated by PCR amplification of the 
entire mISG15-pET15b construct except the N-terminal domain, followed by NdeI 
digestion and then ligation. Additional constructs of ISG15 from the sheep Ovis aries 
(NCBI reference sequence NP_001009735.1), the northern tree shrew, Tupaia belangeri 
(GenBank AFH66859.1), and from the jackknife fish, Oplegnathus faciatus (GenBank 
BAJ16365.1) were designed with the same C-terminal additional amino acids as the pro 
form of human ISG15 (hproISG15) construct, GTEPGGRSGHHHHHH, generating 
constructs termed sheep-proISG15, Nshrew-proISG15, and fish-proISG15, respectively.  
These constructs were incorporated into pET15b using NdeI and BamHI restriction sites.  
The vOTU and ISG15 constructs were introduced into E. coli BL21 (DE3) competent 
cells by heat-shock transformation. The mISG15 construct was heat-shock transformed 
into BL21 (DE3)-CodonPlus competent cells. The resulting plasmids were then purified, 
restriction analyzed, and sequenced to verify the construct. The hproISG15 construct was 
purchased from Boston Biochem.  
Expression of vOTUs and ISG15s 
For vOTU enzymatic studies, E. coli harboring vOTUs from CCHFV, ERVEV, 
mISG15-pET15b, CmISG15-pET15b, or a proISG15 construct were grown at 37 ˚C in 
LB broth containing 100 µg/mL of ampicillin until the optical density at 600 nm reached 
0.6. Expression of the vOTU, mISG15, CmISG15, or proISG15 gene was induced by the 
addition of IPTG to a final concentration of 0.8 mM. The culture was further grown for 4 
hrs at 37 ˚C and then centrifuged at 6,000xg for 10 minutes. CmISG15-pTYB2 was 
grown similarly, but with an induction by the addition of IPTG to a final concentration of 
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0.5 mM, grown at 18˚C overnight. Mutants of vOTUs and CmISG15 were grown the 
same as their parent strains. Cells were collected and stored at -80 ˚C until use.  
Purification of vOTUs and mISG15 
All vOTUs were purified according to the previously published protocol 
(Capodagli et al. 2011). Purification of mISG15-pET15b was performed by 
enzymatically lysing cells resuspending cells in 500 mM NaCl, 50 mM Tris [pH 7.5], and 
1 mM Tris (2-carbozyethyl) phosphine hydrochloride [TCEP-HCl] plus lysozyme. The 
solution was then sonicated on ice at 50% power on five seconds, off five seconds for 10 
minutes total, using a Sonic Dismembrator Ultrasonic Processor (Fisher Scientific). 
Insoluble debris was removed by centrifugation at 17,000xg for 45 minutes. The clarified 
extract was filtered with a 0.80 µm filter and then poured over 2 mL of Ni-NTA beads. 
The beads were washed with 10 mL lysis buffer supplemented with 10 mM imidazole, 
and eluted with 10 mL lysis buffer supplemented with 250 mM imidazole.  The elution 
was then injected on a Superdex75 size-exclusion column and eluted with a buffer 
containing 200mM NaCl and 50 mM HEPES [pH 8.0]. All final protein concentrations 
were determined by absorbance at 280 nm using calculated extinction coefficients (Gill 
and von Hippel 1989). 
Purification of CmISG15-pTYB2 was performed by chemically lysing cells by 
resuspending cells in CmISG15 lysis buffer (25 mM HEPES pH 6.8, 50 mM sodium 
acetate, and 75 mM NaCl), augmented with 0.16% Triton X-100. The solution was then 
sonicated on ice at 50% power on five seconds, off five seconds for 10 minutes total. 
Insoluble debris was removed by centrifugation at 17,000xg for 45 minutes. The clarified 
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extract was filtered with a 0.80 µm filter and then poured over a chitin column pre-
equilibrated with CmISG15 lysis buffer. The column was washed with three column 
volumes of CmISG15 lysis buffer, followed by resuspension of the beads in two column 
volumes of CmISG15 lysis buffer supplemented with 250 mM sodium 2-
mercaptoethanesulfonate (MESNA). The resuspension was rocked gently overnight at 4 
˚C to allow the MESNA to cleave the CmISG15 protein off of its chitin binding fusion 
tag. The chitin bead / protein solution was poured into a XK 26/40 GE column and the 
flow-through was collected. The resulting CmISG15 thioester solution was then 
concentrated to reduce the volume to 20 mL.  Then 480 µL 5 M NaOH and 1.84 g 
propargylamine were added to the CmISG15 thioester, which was then incubated 
overnight at 4°C to create the suicide substrate, CmISG15-PA. Purified ERVE vOTU 
was added directly to the solution containing CmISG15-PA in equi-molar ratios, and was 
incubated at room temperature for 4 hours to create the ERVE vOTU-CmISG15 
complex. This protocol was adapted from previously described methods (Messick et al. 
2008, Wilkinson, Gan-Erdene, and Kolli 2005), and is illustrated in Fig. 6. The complex 
was further purified by anion exchange chromatography, eluting from a GE MonoQ 
10/100 column using a linear gradient from 50 mM Tris [pH = 7.3] to 50 mM Tris [pH = 
7.3], 1 M NaCl, followed by size exclusion chromatography on an AP-1 (Waters) column 
packed with Superdex75 resin preequilibrated with 100 mM NaCl, 5 mM Hepes [pH = 
7.5], 2 mM DTT.  
  
 25 
  
Fi
gu
re
 6
: G
en
er
at
in
g 
E
R
V
E
vO
T
U
-C
m
IS
G
15
 c
om
pl
ex
. (
a)
 C
le
av
ag
e 
of
 C
m
IS
G
15
 fr
om
 C
hi
tin
 b
in
di
ng
 d
om
ai
n 
fu
si
on
 p
ro
te
in
 b
y 
m
er
ca
pt
oe
th
an
es
ul
fo
na
te
. (
b)
 D
er
iv
iti
za
tio
n 
of
 C
-te
rm
in
us
 o
f C
m
IS
G
15
 b
y 
pr
op
ar
gy
la
m
in
e 
(P
A
) t
o 
cr
ea
te
 su
ic
id
e 
su
bs
tra
te
 C
m
IS
G
15
-P
A
. (
c)
 
C
om
pl
ex
at
io
n 
of
 C
m
IS
G
15
-P
A
 w
ith
 E
R
V
E 
vO
TU
 to
 c
re
at
e 
co
va
le
nt
ly
 b
ou
nd
 E
R
V
Ev
O
TU
-C
m
IS
G
15
 c
om
pl
ex
 fo
r c
ry
st
al
liz
at
io
n 
 26 
Crystallization of ERVE vOTU-CmISG15 
Purified ERVE vOTU-CmISG15 was concentrated to 12.5 mg/mL using Vivaspin 
6 10-kDa MWCO concentrators and filtered using a 0.22 µm pore size Costar spin filter, 
and screened against a panel of QIAGEN NeXtal Suites using a TTP Labtech Mosquito. 
Initial screening resulted in several hits of needle-like crystals, the most viable of which 
formed in 6% PEG 6000, 0.1 M citric acid [pH = 4.6]. These were further optimized 
utilizing the Additive HT Screen from Hampton Research. Final rod-shaped ERVE 
vOTU-CmISG5 crystals were obtained through vapor diffusion using a 500 µL reservoir 
with 2 µL hanging drops mixed 1:1 with protein solution and reservoir solution 
supplemented with 0.2 µL 3.0 M NDSB-195. The crystal was transferred to a 
cryoprotective solution of 30% PEG 6000, 0.1 M citric acid [pH = 4.6], and then flash 
cooled in liquid nitrogen. The frozen crystal was mounted under a stream of dry N2 at 
100 K. An ERVE vOTU-CmISG15 data set with resolution of 2.47 Å was collected at the 
Advanced Photon Source (APS) beamline BM-22 at 1.00 Å with a MAR300hs detector. 
X-ray images were indexed, processed, integrated, and scaled using HKL2000 
(Otwinowski and Minor 1997). An initial phase solution was elucidated using a 
homology model based on the DUB vOTU-Ub structure 4HXD using Phaser. The 
structure was refined using iterative cycles of model building and refinement using 
COOT and PHENIX, respectively (Emsley and Cowtan 2004, Adams et al. 2010). Water 
molecules were added to the 2Fo-Fc density peaks of  >1σ using the Find Water COOT 
program function. The final model was checked for structural quality using the CCP4 
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suite programs Procheck and Sfcheck. The data refinement statistics are shown in Table 
1. 
  
 Erve-CmISG15
Data Collection 
 Space Group P 4 3 
 Unit Cell Dimensions
   a, b, c (Å) 66.0, 66.0, 122.0
   α=β=γ (degrees) 90.0, 90.0, 90.0
 Resolution (Å) 50.0-2.47
 No. Reflections Observed 36,660
 No. Unique Reflections 18,742
 Rmerge (%) 13.6 (55.9)*
 I/σI 11.5 (2.56)*
 % Completeness 100.0 (100.0)*
Refinement
 Resolution Range 50.0-2.47
 No. Reflections in Working Set 17,722
 No. Reflections in Test Set 986
 Rwork (%) 18.3
 Rfree (%) 23.3
 Mean B-factor (Å2) 16.2
   Protein B-factor (Å2) 15.3
   Water B-factor (Å 2) 22.5
RMS deviation:
   Bond Lengths (Å) 0.009
   Bond Angles (degrees) 1.43
Protein / Water Atoms 3829/251
Monomers in Asymmetric Unit 2
* The last resolution shell is shown in parentheses.
Table 1: Data Collection and Refinement Statistics
a Rmerge=ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h), where Ii(h) is the ith 
measurement and 〈I(h)〉 is the weighted mean of all 
measurements of I(h).
b Rwork and Rfree=h(|F(h)o|−|F(h)c|)/h|F(h)o| for reflections in 
the working and test sets.
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Site Directed Mutagenesis 
Mutants of CCHF vOTU were generated using QuikChange site-directed 
mutagenesis according to the manufacturer’s protocol (Agilent Technologies, Inc.). The 
resulting mutant plasmids were introduced into E. coli XL1-Blue Supercompetent cells 
by heat shock transformation and were then propagated, purified for sequence 
verification, and transformed into E. coli BL21(DE3) cells for enzyme expression. The 
complete coding regions for all mutant enzymes were sequenced by Eton Bioscience, Inc. 
Fluorescent deISGylation Assay 
All assays were performed in duplicate in 100 mM NaCl, 50 mM HEPES [pH 
7.5], 0.01 mg of bovine serum albumin [BSA]/ml, 5 mM dithiothreitol [DTT] using a 
Corning Costar half-volume black 96-well plate with a reaction volume of 50 µl. The 
rates of the reactions were observed using a CLARIOstar series plate reader (BMG 
LABTECH). Specifically, the increase in fluorescence (excitation λ, 360 nm; emission, 
460 nm) of 7-amino-4-methylcourmarin (AMC) upon cleavage from human ISG15-AMC 
(hISG15-AMC) (Boston Biochem, MA) was monitored for each of the vOTUs. A 
calibration curve for AMC was generated by addition of excess vOTU to various 
concentrations of Ub-AMC, and the reactions were allowed to run until the fluorescence 
signal was no longer increasing with time. The resulting maximum fluorescence values 
were plotted to determine the slope and subsequently create a calibration curve. 
Mouse ISG15 Competition Assay 
The ability of 4 nM vOTU from CCHF vOTU and ERVE vOTU to cleave 2 µM 
hISG15-AMC in the presence of unlabeled mISG15 (120 µM) or hISG15 (120 µM) was 
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observed by measuring the increased fluorescence of free AMC (excitation λ, 360 nm; 
emission, 460 nm) on an Infinite M1000 series plate reader (Tecan). Unlabeled mISG15 
was obtained as described above, whereas hISG15 was acquired from a commercial 
source (Boston Biochem). All assays were performed in buffer 200 mM NaCl, 50 mM 
HEPES [pH 8.0], 0.01 mg of BSA/ml, 5 mM DTT using a Corning Costar half-volume 
black 96-well plate with a reaction volume of 50 µl. The ability of 4 nM CCHF vOTU to 
cleave 1 µM hISG15-AMC in the presence of mISG15 (700 µM), or CmISG15 (700 µM) 
was measured as above using a CLARIOstar series plate reader (BMG LABTECH).   
Pro-ISG15 Cleavage Assay 
10 µM of purified sheep-proISG15, Nshrew-proISG15, or fish-proISG15, or 
hproISG15 (Boston Biochem, MA) were incubated with 20 nM CCHF, ERVE, NSD 
vOTU, or SARS PLpro in 100 mM NaCl, 5 mM HEPES [pH 7.5], and 2 mM DTT at 37 
˚C. Reactions were stopped at various times over 1 hour by mixing 9 µL of each reaction 
with 2 × SDS-Tricine sample buffer and heating at 95 ºC for 5 minutes. Results were 
visualized on 10 – 20% Mini-PROTEAN® Tris-Tricine Precast Gels (Bio-Rad, CA). 
Results 
Species Specificity of CCHF and ERVE vOTU for ISG15 
Unlike Ub, which is highly conserved among eukaryotes, ISG15 and its known 
homologs contain significant sequence variability, even among mammals. Previously, 
studies have suggested that vOTUs may prefer to cleave hISG15 or equivalent homologs 
specific to the species they infect(Capodagli et al. 2011). To investigate the effect of 
species diversity in ISG15s on vOTUs’ ability to cleave these conjugates, unlabeled 
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hISG15 and mISG15 were used as competitive inhibitors against vOTUs from CCHFV 
and ERVEV. Predictably, both vOTUs show >90% decreases in their abilities to cleave 
hISG15-AMC in the presence of unlabeled hISG15. However, the presence of unlabeled 
mISG15 has a divergent effect between the two vOTUs. For CCHF vOTU, mISG15 lacks 
appreciable ability to interfere with this vOTU’s cleavage of hISG15-AMC, revealing 
that CCHF vOTU substantially prefers hISG15 to mISG15 (Fig. 7). Interestingly, ERVE 
vOTU is inhibited by approximately 30% at the same mISG15 concentration, suggesting 
that affinity for certain species’ ISG15s, or homologs, may vary among nairovirus 
vOTUs.  
 
Figure 7: Inhibition of CCHF and ERVE vOTU by h/mISG15. Unlabeled m/hISG15 were 
evaluated as inhibitors of CCHF or ERVE vOTU in the hISG15-AMC assay.  
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X-ray Crystallographic Elucidation of ERVE vOTU-CmISG15 Structure 
In order to further understand the structural basis for the multi-species recognition 
by ERVE vOTU, as well as elucidation of the structural features of CmISG15, a 
covalently bound complex of ERVE vOTU and CmISG15 (ERVEvOTU-CmISG15) was 
solved to 2.47 Å (Table 1). As has been found for other nairovirus vOTUs, CCHFvOTU 
and DUGvOTU, the ERVEvOTU possess similar global folds.  It is composed of a core 
of seven β-sheets, flanked by seven α-helices, and three 310 helices (Fig 8a). Interestingly, 
the ERVEvOTU-CmISG15 structure shared several similarities with the DUGvOTU-Ub 
(4HXD) structure reported by Capodagli et al. (2013). Specifically, it possesses the same 
shift at the alpha-3 helix seen with DUG vOTU when compared to CCHF vOTU. This 
helix is partly situated in a highly conserved amino acid sequence, which is flanked by 
more variable regions. In the middle of the α3-helix, where there is a transition from 
conserved to variable region, and positioned such that it is interfacing with the substrate 
binding interface, is CCHF vOTUs R80, which corresponds to Erve vOTUs I83. The 
corresponding ISG15 residues with which R80 and I83 interact are conserved between 
human and mouse ISG15.  Interestingly, upon examination of vOTUs’ interaction with 
their respective ISG15 substrate, the positively charged R80 and hydrophobic I83 each 
favorably interact with the conserved ISG15 region (Fig 8d-f).  The hISG15 is situated 
such that its E132 is interacting with CCHF vOTUs R80, and P132 is shifted away.  
Similarly, the mISG15 is shifted such that its P128 is hydrophobically interfacing with 
ERVE vOTUs I83, while its E130 is not involved in binding (Fig 8d).  This shift is driven 
by the variation in the vOTU, not the substrate.  Variations in substrates are 
 32 
accommodated by the vOTU on the other side of the binding pocket in the β-sheet / 
substrate interface. Specifically, CCHF vOTU’s E128, which faces into the binding 
pocket, interacts with the hISG15 K90 (Fig. 8e).  By comparison, ERVE vOTU’s 
Figure 8: ERVEvOTU-CmISG15 crystal structure. (a) ERVEvOTU-CmISG15 crystal structure 
with ERVE vOTU rendered in light orange, and mISG15 in light blue. (b) Comparison of 
CCHFvOTU-ChISG15 (PDB entry 3PHX) with ERVEvOTU-CmISG15. ERVEvOTU-CmISG15 is 
rendered as in (a), CCHF vOTU is rendered orange, and ChISG15 is blue. Boxed in green is shown in 
detail in (d), boxed in red is shown in (e), and boxed in yellow is shown in (f). (d) Comparison of the 
α3 helix-binding interface between CCHFvOTU-ChISG15 and EVREvOTU-CmISG15, colored as in 
(b). (e) β-sheet / substrate binding interface of CCHF vOTU E128 with hISG15 K90, colored as in (b). 
(f) ERVE vOTU R21 H-bonding with CmISG15 backbone through coordinated water molecule, which 
is represented as a cyan sphere, while proteins are colored as in (b). 
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corresponding I131 does not favorably interact with either hISG15 or mISG15 in that 
location, and its mISG15 substrate is shifted away from this residue.  To compensate, in 
another area of the binding pocket, ERVE vOTUs R21 can hydrogen bond with the 
carbonyl backbone of mISG15 through a coordinated water molecule, where CCHF 
vOTU’s V18 is not favorably interacting with hISG15 (Fig. 8f). 
Inhibition of CCHFvOTU by Mutants of CmISG15 
Upon examination of ERVEvOTU-CmISG15 overlaid with CCHFvOTU-
ChISG15, key areas were identified as possible recognition sites for ERVEvOTU’s 
accommodation of both mISG15 and hISG15. While CCHF vOTU mutants V18R and 
E128I both significantly decreased in activity towards hISG15-AMC by approximately 
50 and 60%, respectively, neither mutation made appreciable gains in recognition of 
CmISG15 by CCHF vOTU (Fig. 9).   
Figure 9: CCHF vOTU mutants inhibition by CmISG15.  
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ProISG15 Gel Shift Assay 
In order to further explore the degree of species preference of varying nairovirus 
vOTUs, special constructs of ISG15 from human, sheep, northern tree shrew, and 
jackknife fish (hproISG15, sheep-proISG15, Nshrew-proISG15, and fish-proISG15, 
respectively) were designed with additional amino acids on the C-terminus.  These amino 
acids are the sequence found on the pro-form on hISG15, plus a His-tag. By eliminating 
variation in this extension of the substrate, variation in the vOTUs’ preference for these 
ISG15s could be investigated. CCHF vOTU readily cleaved the hproISG15 to completion 
within about 10 minutes (Fig. 10). Interestingly, it also cleaved the sheep-proISG15 and 
Nshrew-proISG15 rapidly, and after an extended time, 30-60 minutes, had cleaved a 
small amount of fish-proISG15.  ERVE vOTU completely cleaved the hproISG15 within 
about 60 minutes, had about equal cleavage for the sheep-proISG15, a trace of activity 
toward fish-proISG15, but possessed zero activity toward the Nshrew-proISG15, even 
after 60 minutes. NSD vOTU cleaved both hproISG15 and NShrew-proISG15 
completely after 30 minutes, and showed zero activity toward fish-proISG15. 
Interestingly, it rapidly cleaved the sheep-proISG15 within about 5 minutes.  In contrast 
to the vOTUs, SARS PLpro was also paneled against the pro-ISG15 constructs. SARS 
PLpro exhibited moderate cleavage of hproISG15, leaving a trace amount uncleaved after 
60 minutes, cleaved the sheep- and Nshrew-proISG15s within about 10 minutes, and was 
the DUB which exhibited the most activity toward fish-proISG15, cleaving about 40% 
within 60 minutes (Fig. 10).  While SARS PLpro was more robust than the vOTUs 
towards the fish-proISG15, it still displayed preference for human, N. shrew, and sheep.  
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Figure 10: ProISG15 Gel Shift Assay.  CCHF, ERVE, or NSD vOTU, plus SARS 
PLpro were evaluated for cleavage of human, sheep, N.shrew, and fish proISG15. 
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Discussion 
Primary Structure Determinant of Substrate Preference 
In Capodagli et al. (2013), it was determined that the primary structure of the 
CCHF and DUG vOTUs were key factors in substrate preference, and that global 
secondary and tertiary structural features were mainly conserved, with the minor 
exception of a shift of the α3-helix.  In a similar manner, ERVE vOTU possesses 
conserved global folds of other nairovirus vOTUs, with a shift in the α3-helix similar to 
DUG vOTU. Ultimately, while the primary structure appears to be the driving force in 
determining substrate recognition, it results in slight shifting of the substrate within the 
binding pocket. This shift appears to accommodate varying substrates by balancing 
favorable contacts in different area of the binding pocket, specifically balancing favorable 
amino acid interactions on the binding interface between the β-sheet and substrate 
interface on the opposite side of the binding pocket as the α3-helix (Fig. 11). These slight 
adjustments of the substrate within the binding pocket allow the vOTUs to possess their 
dual activities towards varying substrates. While others have identified specific amino 
acid residues which can modulate the activity of CCHF or DUG vOTU toward Ub or 
ISG15 (James et al. 2011, Akutsu et al. 2011, Capodagli et al. 2013), there do not appear 
to be global control switches for Ub and ISG15 activity, but rather a collection of 
variations to the binding interfaces which have individually evolved for each vOTU.  
Furthermore, this shifting of substrate within the binding pocket may ultimately be what 
allows vOTUs to appear to possess activity towards substrates to which they could not 
have had evolutionary pressure to develop activity towards, as is the case with Turnip 
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Yellow Mosaic Virus (TYMV) as shown by Capodagli et al. (2013), which can be 
shown, at sufficiently high concentrations, to cleave hISG15-AMC, which is not known 
to exist in plants. Along a similar line, CCHF vOTUs lack of recognition towards 
mISG15 creates inherent problems for any mouse model systems for study of CCHFV. 
Under biologically relevant conditions, CCHF vOTU does not possess sufficient 
recognition of mISG15 to interfere with its role in viral immune response in mice. 
 
  
Figure 11: Comparison of Ub and ISG15 bound by CCHF vOTU, ERVE vOTU and DUG vOTU. 
the vOTUs from CCHFvOTU-Ub (PDB ID: 3PRP), DUGvOTU-Ub (PDB ID: 4HXD), CCHFvOTU-
ChISG15 (PDB ID: 3PHX), and ERVEvOTU-CmISG15 were structurally aligned using SSM 
Superpose, and the resulting overlay of their respective substrates is shown. Ub bound to CCHF vOTU 
is shown green, Ub bound to DUG vOTU is red, ChISG15 bound to CCHF vOTU is cyan, and 
CmISG15 bound to ERVE vOTU is blue. 
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Diversity of ISG15 Recognition 
Based on the inability of mISG15 to inhibit CCHF vOTU, it was hypothesized 
that CCHF vOTU was a more selective vOTU than ERVE vOTU, with a high specificity 
towards hISG15.  The proISG15 gel shift assay revealed that CCHF vOTU can, in fact, 
cleave a variety of species’ ISG15s. CCHF vOTU’s high activity towards hISG15 and 
NSDV’s strong preference and activity toward sheep ISG15 are in line with the role of 
the vOTU as a virulence factor through targeting ISG15 in species resulting in a high 
mortality rate. However, while a high activity toward ISG15 may be an indicator for 
virulence, it alone cannot explain why CCHFV is only found to be lethal in humans, 
when it also readily cleaves sheep and shrew ISG15. While the activity of the vOTU has 
been identified as one potential virulence factor, it is apparent that there are other factors, 
which have yet to be identified, that may work in concert with the robust vOTU 
deISGylation to result in high mortality for specific species.  
Intriguingly, ERVE vOTU, which was inhibited by mISG15, and also readily 
cleaves sheep and human proISG15s, had no measurable activity towards the Northern 
shrew’s ISG15. While ERVEV was isolated from the white-toothed shrew, this may 
represent another possible outcome of mutations that favor one substrate, such as Ub, or 
to become specific to one species’ substrate, such as ISG15, when balancing competing 
factors affecting the vOTUs substrates preferences, and still maintaining necessary 
proteolytic activity for viral polypeptide processing. Favoring one role over another may 
cause a loss in activity for one and gains for another. Alternatively, in the possible 
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absence of a strong IFN response to infection by ERVEV in shrew, there may not be 
pressure for the ERVEV to develop activity toward the shrew’s ISG15.  
Including SARS PLpro in the panel of DUBs cleaving proISG15 constructs 
provides insight into the behavior of a different class of DUB.  SARS PLpro has been 
shown to be a di-distributive DUB, preferentially cleaving K48 linked poly-UB, leaving 
behind mono-Ub on substrates (Ratia et al. 2014).  While it cleaved all of the ISG15s 
paneled, it may be less driven by primary structure, as is seen with the vOTUs, and more 
by tertiary structural folds.  It was seen by Ratia et al. (2014) that its specificity toward 
K48 poly-Ub over K63 poly-Ub was driven by a secondary binding site which 
accommodated K48 over the linear, K63 linkage, with the more condensed, bent structure 
of K48 nested into both its proximal and distal binding sites. It may be that the flexibility 
of the middle, hinge region of ISG15s allow them to conform to fit in the binding site of 
SARS PLpro. While only the C-terminal lobe of ISG15 is involved in binding to vOTU 
active sites, based on the manner in which K48 Di-Ub is proposed to fit into the SARS 
PLpro active site, it is likely that both lobes of ISG15 are involved in binding to SARS 
PLpro.  
Implications for Mouse Model Systems 
The elucidation of the x-ray structure of CmISG15 not only provides the first 
structural information for mISG15, but opens the door for further developing methods for 
potentially utilizing mouse model systems for study of viruses which express vOTUs, 
such as CCHFV. Current studies have demonstrated how to turn on and off specific 
substrate activities through mutation of select amino acids.  Based on the findings that the 
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primary structure is key in dictating substrate selectivity, it is plausible that a hybrid 
vOTU could be developed which possesses robust activity towards mISG15, which could 
be investigated for a mouse model system for the development of therapeutics for 
CCHFV. 
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CHAPTER THREE: STRUCTURAL AND BIOCHEMICAL 
CHARACTERIZATION OF HUMAN ADENYLOSUCCINATE LYASE (ADSL) 
AND THE R303C ADSL DEFICIENCY ASSOCIATED MUTATION 
Introduction 
Adenylosuccinate lyase (ADSL) deficiency is a rare autosomal recessive disorder 
characterized by serious neurological and physiological symptoms such as psychomotor 
retardation (PMR), expression of autistic features, structural brain abnormalities, axial 
hypotonia, seizures, peripheral hypotonicity, ataxia, muscle wasting, growth retardation 
and strabismus (Spiegel, Colman, and Patterson 2006, Mouchegh et al. 2007, Gitiaux et 
al. 2009). More than 60 cases of ADSL deficiency have been reported worldwide, but it 
is widely considered to be underdiagnosed (Köhler et al. 1999, Jurecka et al. 2008, 
Ciardo, Salerno, and Curatolo 2001). ADSL deficiency is clinically diagnosed by 
elevated levels of succinylaminoimidazolecarboxamide riboside (SAICAr) and 
succinyladenosine (S-Ado) in urine, plasma, and cerebrospinal fluid (Georges and Berghe 
1984). Three distinct phenotypic groups have been established: 1) Neonatal; 2) Type I; 3) 
Type II. The neonatal form results in fatal neonatal encephalopathy and has a S-
Ado:SAICAr ratio of <1. Type I patients experience early onset, severe PMR, and have a 
ratio of ~1. Type II patients experience later onset with mild PMR, and have a ratio of 2–
4 (Van den Bergh, Vincent, Jaeken, and Berghe 1993). There are three main hypotheses 
that describe the difference in ratio: 1) nonparallel reduction in the enzyme’s activity on 
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its substrates; 2) differential dephosphorylation or transport of the substrates out of the 
cells (Van den Bergh, Vincent, Jaeken, and Berghe 1993, Hürlimann et al. 2011), and 3) 
inability of ADSL mutant protein to form an active purinosome, which is formed when 
purine synthesis is required and is needed for appropriate channeling of 
succinylaminoimidazolecarboxamide ribonucleotide (SAICAR)  through the de novo 
purine synthesis pathway (Baresova et al. 2012). ADSL carries out two non-sequential 
steps of de novo AMP synthesis, the conversion of SAICAR and succinyladenosine 
monophosphate (SAMP) into aminoimidazolecarboxamide ribotide (AICAR) and 
adenosine monophosphate (AMP), respectively, with the concomitant release of fumarate 
in each case (Lundy et al. 2010). The conversion of SAMP to AMP is also part of the 
purine nucleotide cycle. So far, all mutations, with one exception, result in a proportional 
loss of enzyme activity with the two substrates. The ADSL carrying the R303C mutation 
has been observed as a homozygous mutation in two unrelated patients. It is a type II 
mutation and results in the mildest observed form of ADSL deficiency. Interestingly, this 
mutation shows a more severe loss in activity with SAMP than with SAICAR, although 
the extent of disproportionality varies from study to study, perhaps reflecting differences 
in how the enzyme assays were carried out. Some investigators were unable to detect 
activity with SAMP in extracts from fibroblasts (Race et al. 2000), while others found 3% 
of normal activity (Van den Bergh, Vincent, Jaeken, and Berghe 1993). In other cases 
using different recombinant ADSL constructs, 7% and 18 % of wild-type (WT) activity 
was observed with SAMP and 44% with SAICAR (Race et al. 2000, Zikánová et al. 
2010). The reason for the non-parallel loss of activity is not yet understood, nor is the 
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reason why this mutation leads to such a mild phenotype. Hypotheses include the 
possibility that different amino acids in the active site bind the two substrates, that 
cysteine is not able to interact well with SAMP, or that there are alterations in the 
stability of the active site cleft (Race et al. 2000, Zikánová et al. 2010). Crystal structures 
of the bacterial ADSL and other studies have provided insight into the active site and the 
catalytic mechanism; however these studies predominately use bacterial ADSL from 
organisms such as Thermotoga maritima or Escherichia coli (Toth et al. 2000, Tsai et al. 
2007). T. maritima and Homo sapiens have a sequence identity of 25% and similarity of 
57%. E. coli and H. sapiens have a sequence identity of 23% and a similarity of 57% 
(Fig. 12). ADSL was found in these bacterial species to function in the pathway as a 
homotetramer. Interestingly, three monomers contribute to each of the four active sites in 
the tetramer (Sivendran and Colman 2008, Brosius and Colman 2002). The use of 
Bacillus subtilis ADSL in particular as a model to study properties of mutant enzymes in 
some cases involved modification of additional amino acid residues in the B. subtilis 
ADSL to more closely resemble human ADSL (Sivendran et al. 2004, Palenchar and 
Colman 2003). However, attempts to make use of a B. subtilis model system to replicate 
the R303C phenomenon have proven difficult because B. subtilis and H. sapiens only 
have a sequence identity of 30% and a similarity of 63%. Specifically, the sequence 
diversity of B. subtilis and H. sapiens results in multiple alterations within the active site 
including, but not limited to, an asparagine residue in place of the corresponding R303 in 
human ADSL, as well as an arginine residue in place of human corresponding T354. Not 
surprisingly, the removal of B. subtilis’s asparagines at the corresponding human ADSL 
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R303 position for cysteine did not generate a disproportional reduction in catalytic ability 
(Palenchar and Colman 2003, Sivendran et al. 2004). This observation as well as others 
suggest that the study of the bacterial enzyme, while initially useful for understanding 
some of the basic features of ADSL, such as its tetrameric nature and participation of 
three subunits in forming each active site, may not be as useful for understanding the 
effects of various disease causing mutations on the human enzyme. Only limited 
structural information exists of human ADSL active site in the unpublished SAMP bound 
and S-AMP/AMP-fumarate bound PDB deposited entries (2J91, 2VD6). Current studies 
on disease-associated mutations of human ADSL have focused on correlation of substrate 
activity with clinical phenotypes, thermal stability of ADSL, activity of hybrid WT 
ADSL and mutants, and global changes in structure (Zikánová et al. 2010, Ariyananda et 
al. 2011, Ariyananda et al. 2009, Race et al. 2000, Kmoch et al. 2000). They have not 
investigated local structural changes or binding properties to the products within the 
ADSL active site. In this study, we present structural and biochemical characterization 
data of WT and mutant R303C ADSL by enzyme kinetics, product binding by isothermal 
titration calorimetry (ITC), and X-ray crystallography to reveal the effects of the R303C 
mutation that results in nonparallel reduction in enzyme activity. 
Experimental Procedures 
Materials 
Chemicals, biochemicals, buffers, and solvents were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO), Fisher Scientific Inc. (Pittsburgh, PA), Fluka 
Chemical Corp. (Milwaukee, WI), or EM Science (Cincinnati, OH). The Centricon and 
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Ultrafree centrifugal filter devices were obtained from Millipore Co. (Billerica, MA). 
Nickel-nitrilotriacetic acid-agarose, a QIAspin kit, and high throughput crystal condition 
screens were purchased from QIAGEN. Additive HT Screen was purchased from 
Hampton Research. QuikChange site directed mutagenesis kit was purchased from 
Stratagene. SAICAR was prepared enzymatically from AICAR purchased from Sigma-
Aldrich Chemical Co. as described by Zikánová et al. (2005). Enzymes and reagents used 
for molecular biology procedures were obtained from New England Biolabs, Inc. 
(Ipswich, MA).  
Site-directed mutagenesis, Enzyme Expression, and Purification. 
The initial WT ADSL construct was obtained from Dr. Roberta F. Colman, 
Department of Chemistry and Biochemistry, University of Delaware, Newark, DE.  The 
full description of the initial WT ADSL construct is described in Lee and Colman (2007). 
In short, the full length human ADSL gene (1-484 residues) was constructed in pET-14b 
vector containing a 5’end NdeI restriction site and a 3’-end BlpI restriction site and a 
thrombin cleavable N-terminal histidine tag. In order to overexpress the human enzyme 
in E. coli, the vector was transformed into E. coli Rosetta 2(DE3)pLysS. The WT and 
R303C ADSL were purified to homogeneity using a Qiagen Ni-NTA column. Purity was 
assessed by SDS-PAGE gel electrophoresis (data not shown). After purification, protein 
was stored in Enzyme Storage Buffer (50 mM potassium phosphate buffer, pH 7.0, 
containing 150 mM KCl, 1 mM DTT, 1 mM EDTA, and 10% (v/v) glycerol) at -80°C. 
Introduction of point mutations in the human ADSL plasmid was done using QuikChange 
site-directed mutagenesis. The QIAspin kit was used for cDNA extraction and 
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purification. DNA sequencing was performed at the CU Cancer Center DNA Sequencing 
& Analysis Core to confirm mutations. Slight modifications were made to the 
purification for ITC and X-ray Crystallography. Following the purification using the 
Qiagen Ni-NTA column, thrombin was added to the eluted fraction and it was dialyzed 
overnight at 4°C in ADSL Running Buffer (5 mM HEPES pH 7.0, 150 mM KCl, 2 mM 
DTT) to cleave the His-tag. The protein was purified by size exclusion chromatography 
using S200 sepharose resin and concentrated to 10 mg/mL for crystallography, and to 
200-400 µM for ITC. Concentrations were measured by the absorbance at 280 nm using 
an experimentally determined extinction coefficient of 0.782 L g-1cm-1 (43,150 M-1cm-1) 
for thrombin cleaved ADSL and 0.770 L g-1cm-1 for His-tagged ADSL following 
previously established procedures (Gill and von Hippel 1989). 
Static Light Scattering 
Size Exclusion Chromatography-Multi-Angle Light Scattering measurements 
were performed on a Wyatt miniDAWN TREOS connected to a Shimadzu UFLC and a 
Wyatt WTC-030S5 size exclusion column. Samples of 350 µg of His-tagged ADSL 
diluted in Enzyme Storage buffer were run in duplicate. PBS was used as the mobile 
phase and flowed at 0.5 mL/min. Calibration was checked using 2 mg/mL bovine serum 
albumin. Data were analyzed with ASTRA software, and 0.185 was used as the dn/dc 
value. 
Enzyme Assays and Kinetic Studies 
Enzyme kinetic experiments were performed on a UV-Vis Spectrophotometer 
Evolution 3000 from Thermo Scientific using 1 mL quartz cuvettes at 25°C. ADSL with 
 47 
the His-tag intact was used for enzyme assays, as it has been shown that the His-tag does 
not affect ADSL activity for SAMP (Lee and Colman 2007). Experiments were run with 
concentrations of 0.11 mg/mL and 0.19 mg/mL for WT and R303C ADSL, respectively. 
Frozen samples were incubated for ~2 hours at 25°C before measurements were taken to 
assure restoration of full activity (Lee and Colman 2007). SAMP enzyme assays of 
ADSL were measured in triplicate at 25°C in 40 mM Tris-HCl (pH 7.4) with varying 
concentrations of SAMP (1 - 60 µM). Specific activity was measured from the decrease 
in absorbance of SAMP at 282 nm as it was converted to AMP and fumarate. The assay 
was monitored over 30 seconds in a 1 mL volume. The difference in extinction 
coefficient of 10,000 M-1 cm-1 between SAMP and AMP was used to calculate the 
specific activity. SAICAR enzyme assays of ADSL were measured in triplicate at 25°C 
in 40 mM Tris-HCl (pH 7.4) with varying concentrations of SAICAR (1 - 100 µM). 
Specific activity was measured from the decrease in absorbance of SAICAR at 269 nm as 
it was converted to AICAR and fumarate. The assay was monitored over 30 seconds in a 
1 mL volume. The difference in extinction coefficient of 700 M-1 cm-1 between SAICAR 
and AICAR was used to calculate the specific activity. To determine the kinetic 
constants, the initial velocity data were fitted to the Hill equation, υ = 
Vmax*[S]n/(K0.5n+[S]n) for WT and R303C ADSL and υ = Vmax*[S]/(KM+[S]) for R303C 
ADSL, using the Enzyme Kinetics Module 1.3 of Sigma Plot version 10 (SPSS Inc.). The 
kcat value was calculated from Vmax and the enzyme concentration [E] via the equation kcat 
= Vmax/[E]. 
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Isothermal Titrations Calorimetry (ITC) 
ITC experiments were conducted using a NANO-ITC system (TA Instruments, 
Utah, USA). Thrombin cleaved WT ADSL was dialyzed overnight against a solution of 
25 mM HEPES pH 7.0, 150 mM KCl, and 2 mM DTT. AMP was brought to a 
concentration of 2.5 mM using the buffer in which WT ADSL was dialyzed. ITC runs of 
WT ADSL with AMP were performed in duplicate and comprised of a single 1µl 
injection followed by 24, 2 µl injections for a total of 25 injections of 2.5 mM AMP into 
0.250 mM WT ADSL. Each injection was spaced 250 seconds apart. ITC experiments 
were performed in an identical method, injecting AICAR instead of AMP into 0.225 mM 
WT ADSL. In addition, AMP and AICAR were titrated in an equal manner into 0.280 
mM R303C ADSL. Data sets were analyzed with NanoAnalyze software and fit to an 
independent model concurrently with a blank constant model to adjust for heat of 
dilution. 
Crystallization of WT and R303C ADSL 
Initial crystal conditions for both WT and R303C ADSL were determined from 
high-throughput screening of Qiagen Nextel screens, Classics and PEG I, in a 96 sitting 
drop format using an Art Robbins Phoenix robot. The drops consisted of 0.4 µL protein 
solutions and 0.4 µL precipitate in a 100 µL reservoir. Initial screening exhibited multiple 
hits; however, a solution containing 0.1 M Tris pH 8.0, and 20% (w/v) PEG 6000 
produced the most viable crystals for WT ADSL, and 0.1 M Tris pH 8.5 and 20% (w/v) 
PEG 8000 for the ADSL mutant R303C. These crystals were then optimized using 
Additive HT Screen from Hampton Research. Final WT and R303C ADSL crystals were 
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obtained through vapor diffusion using a 500 µL reservoir with 4 µL drops mixed 1:1 
with protein solution and, for native ADSL, a precipitant gradient of 18-28% (w/v) PEG 
6000, 0.1 M Tris pH 8.0, and 12.5 mM MgCl2•6H2O, and for R303C, a precipitant 
gradient of 18-28% (w/v) PEG 8000, 0.1 M Tris pH 8.5, and 12.5 mM spermine 
tetrahydrochloride. 
X-ray Structural Determination of ADSL Structures 
All X-ray native datasets were collected using crystals mounted on nylon loops 
and submerged in a 5 µL cryo solution of 26% (w/v) PEG 6000 and 0.1 M Tris pH 8.0 
for WT ADSL, and 26% (w/v) PEG 8000, 0.1 M Tris pH 8.5 for R303C ADSL. In order 
to preserve the crystals they were submerged and flash frozen in liquid nitrogen.  Frozen 
crystals were mounted under a stream of dry N2 at 100 K. A WT ADSL dataset with 
resolution to 2.70 Å and ADSL mutant R303C dataset with resolution to 2.60 Å were 
collected at the 21-ID-D Life Science-Collaborative Access Team beamline at the 
Advanced Photon Source Synchrotron. Both datasets were collected at 0.9789 Å with a 
MarMosaic300 CCD detector (Rayonix). All data was subsequently processed and scaled 
using Scalepack (Winn et al. 2011) and subsequent phases were determined and refined 
using Phaser (McCoy et al. 2007). Initial models for both WT and R303C ADSL were 
elucidated by molecular replacement using ADSL structure 2J91 as a search model for 
Phaser (McCoy et al. 2007). Both structures were refined using iterative cycles of model 
building and structure refinement using WinCOOT (Emsley and Cowtan 2004) and 
REFMAC (Murshudov, Vagin, and Dodson 1997), respectively. Water molecules were 
added to 2Fo-Fc density peaks that were greater than 1σ using the “Find Water” 
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WinCOOT program function. The final model was checked for structural quality using 
the CCP4 suite programs: Procheck and Sfcheck. Data processing and refinement 
statistics are shown in Table 2.  
 WT APO R303C ADSL
Data Collection 
 Space Group P 2 12 12 1 P 2 12 12 1
 Unit Cell Dimensions
   a, b, c (Å) 85.9, 105.1, 215.0 85.8, 105.6, 217.2
   α=β=γ (degrees) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
 Resolution (Å) 50.0-2.70 50.0-2.60
 No. Reflections Observed 241,786 263,513
 No. Unique Reflections 48,725 58,820
 Rmerge (%) 10.3 (63.1)* 12.4 (35.0)*
 I/σI 14.2 (4.3)* 18.9 (4.8)*
 % Completeness 89.6 (90.2)* 95.4 (97.1)*
Refinement
 Resolution Range 50.0-2.70 50.0-2.60
 No. Reflections in Working Set 45,972 55,609
 No. Reflections in Test Set 2,450 2,979
 Rwork (%) 24.3 23.0
 Rfree (%) 29.2 29.8
 Mean B-factor (Å2) 27.5 55.1
   Protein B-factor (Å2) 27.6 54.9
   Water B-factor (Å 2) 19.2 50.1
RMS deviation:
   Bond Lengths (Å) 0.01 0.01
   Bond Angles (degrees) 0.9 1.01
Protein / Water Atoms 14,605/214 14,764/144
Monomers in Asymmetric Unit 4 4
* The last resolution shell is shown in parentheses.
Table 2: Data Collection and Refinement Statistics ADSL
a Rmerge=ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h), where Ii(h) is the ith measurement 
and 〈I(h)〉 is the weighted mean of all measurements of I(h).
b Rwork and Rfree=h(|F(h)o|−|F(h)c|)/h|F(h)o| for reflections in the 
working and test sets.
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Modeling of AMP/AICAR and Fumarate Binding in the Active Site 
Apo structures of WT ADSL with either AICAR or AMP were neutralized with 
the TLEAP module from the Amber10 simulation package (Pearlman et al. 1995, Case et 
al. 2005) and solvated using TIP3P water molecules (Jorgensen et al. 1983). The final 
system was then energy minimized using the Amber 10 simulation package to obtain the 
final structure. Initially, each system’s protein was restrained, and the solvent was 
minimized for 5,000 steps to remove any unfavorable contacts that occurred within the 
water. Then, each system (solvent and molecule) was allowed to energy minimize for 
20,000 steps, starting with 10,000 steps of steepest descent and switching to 10,000 more 
steps of conjugate gradient minimization. The force field used was ff99SB (Hornak et al. 
2006). We removed residues outside of 30 Å from AMP/AICAR active site. This was 
done to reduce computational demand by ignoring distant parts of the protein not relevant 
for the present problem. However, 30 Å was long enough to focus on a sufficiently large 
region around the active site to avoid any artifact due to small system size. All the 
calculations were performed at University of Denver’s High Performance Computing 
facility, which is a Linux cluster with 22 twin nodes, each node having eight cores. 
Results 
WT and R303C ADSL Enzyme Kinetics 
To ensure that the previously observed reduction in activity of the ADSL 
possessing the R303C mutation was not due to aberrant tetramer formation or outright 
global instability of the mutated protein in solution, static light scattering was employed 
to determine the polymeric distribution of the R303C and WT ADSL. As expected, WT 
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ADSL is predominantly found to be a tetramer, 92.7 ± 2.6%, with aggregates 
contributing the final percentage. Similarly, R303C ADSL is predominantly a tetramer, 
94.3 ± 0.1%, with aggregates contributing the final percentage. Observed weights of the 
WT and R303C ADSL tetramers were 225.0 ± 2.9 kDa and 214.5 ± 12.2 kDa, which is in 
close agreement with the His-tagged WT and R303C ADSL predicted tetrameric weights 
of 228.4 and 228.1 kDa, respectively, suggesting that the R303C mutation results in no 
degradation of the ADSL tetramer. 
Previously, a report noted that the ADSL carrying the R303C mutation displayed 
nonparallel decrease in activity at a single concentration (Zikánová et al. 2010). 
Additionally, the kinetic parameters for human ADSL utilization of SAICAR have never 
been fully determined. Interestingly, Stone, Zalkin, and Dixon (1993) detail a KM and kcat 
of ADSL for SAICAR. Unfortunately, the boundaries of ADSL were not well established 
at the time of that study, resulting in their use of a 25 amino acid N-truncated version of 
ADSL and not accounting for cooperativity. Unfortunately, a subsequent study by 
Kmoch et al. (2000) also did not account for ADSL cooperativity, nor did they report on 
the R303C mutant. This has left ambiguity to the kinetic parameters surrounding ADSL 
ability to use SAICAR as a substrate. To further investigate the R303C phenomenon and 
determine the KM and kcat of ADSL for SAICAR, kinetic assays were performed on both 
WT and R303C ADSL using SAICAR and SAMP as substrates (Zikánová et al. 2010). 
Both WT and R303C ADSL had measurable activity that could be evaluated by 
monitoring the UV absorbance of either SAMP or SAICAR. As WT ADSL was 
previously reported not to follow simple Michaelis-Menten kinetics for SAMP and 
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perhaps be cooperative, the Hill equation was initially employed for calculating WT 
ADSL’s kinetic parameters (Table 3) (Ariyananda et al. 2009). The resulting Hill 
coefficients of WT ADSL for SAMP and SAICAR are both significantly above one, 
indicating cooperativity for the substrates. The resulting kcat and K0.5 of WT ADSL for 
SAMP was in agreement with a prior study that utilized the non-truncated form of ADSL 
(Ariyananda et al. 2009). For WT ADSL’s utilization of SAICAR, its K0.5 was 1.8 ± 0.1 
µM, which is only slightly higher than SAMP’s. However, WT ADSL’s kcat for SAICAR 
was 1.6 fold higher than that for SAMP suggesting that ADSL is more kinetically 
efficient for the catalysis of SAICAR over SAMP. This is confirmed by WT ADSL’s 
kcat/K0.5 for SAICAR being 2 fold higher than SAMP’s. Additionally, the kcat for both 
substrates was found not to be diffusion limited.  
 
Table 3: Enzymatic Activities of ADSL with SAMP and SAICAR at 25 C 
  SAMP SAICAR 
  WT R303C WT R303C 
kcat,H (1/sec) 52.2 ± 1.8 2.33 ± 0.07 90.2 ± 1.9 27.8 ± 0.8 
kcat,H (%) 100 ± 3 4.5 ± 0.1 100 ± 2 31 ± 1 
K0.5 (µM) 2.1 ± 0.2 2.3 ± 0.12 1.8 ± 0.1 8.4 ± 0.8 
Hill Coeff 1.5 ± 0.2 1.03 ± 0.08 1.22 ± 0.09 0.94 ± 0.06 
kcat,H/K0.5 (sec-1µM-1) 25.0 0.99 49.6 3.37 
kcat,M (1/sec) N/A 2.36 ± 0.04 N/A 27.2 ± 0.4 
kcat,M (%) N/A 4.5 ± 0.1 N/A 30 ± 1 
KM (µM) N/A 2.4 ± 0.2 N/A 7.8 ± 0.4 
kcat,M/KM (sec-1µM-1) N/A 0.99 N/A 3.45 
The kcat, K0.5, KM, and Hill coefficient were determined by varying substrate concentration and fitting 
data to the Hill Equation (H) or the Michaelis-Menten Equation (M) in Sigma Plot. Protein was 
reconstituted for 2 hours at 25 oC prior to measurements. R303C activity is relative to % WT. The 
values are shown along with their standard errors. N/A stands for not applicable. 
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Introduction of the R303C mutation into ADSL has multiple effects. Initially 
expecting similar cooperativity observed in WT ADSL, the Hill equation was utilized 
(Table 3). Unlike WT ADSL, the R303C ADSL demonstrates no cooperativity, with a 
Hill coefficient for both substrates of one. As a result, the simple Michaelis-Menten 
equation was employed for R303C. The R303C ADSL mutation reduces kcat to 4.5% and 
30% of that relative to WT ADSL for SAMP and SAICAR, respectively. Interestingly, 
this 7-fold difference in residual in vitro activity is in line with cell free extract studies of 
a Type II patient’s fibroblasts carrying the R303C mutation, which had 3% of normal 
SAMP activity and 30% of normal SAICAR activity (Race et al. 2000, Van den Bergh, 
Vincent, Jaeken, and Van den Berghe 1993). As a result, the ratio of activity of WT 
ADSL for SAICAR:SAMP is 1.7, which is in agreement with a previously published 
ratio of 1.6, but the ratio of activity for the R303C mutant ADSL shifts to 11.5 
(Ariyananda et al. 2011). Interestingly, KM values of R303C ADSL increased for 
SAICAR compared to that of WT ADSL. The change observed in KM of R303C ADSL 
for SAMP is almost negligible, with the KM for SAICAR increasing more than 4-fold. 
This may initially suggest the mutation affects the ability of R303C ADSL to bind 
SAICAR more than SAMP resulting in the disparity in their cleavage. However, the rate 
of SAICAR cleavage by R303C ADSL is 5 times more rapid than that for SAMP at 
R303C ADSL’s SAMP KM. Therefore, the effect of the R303C mutation on ADSL may 
not solely be reflective in its divergent ability to bind SAICAR and SAMP. It suggests 
that R303C may affect the catalytic mechanism of SAMP and SAICAR in addition to 
binding of the substrates. 
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Isothermal Titration Calorimetry (ITC) 
To explore the possible thermodynamic factors involved in the non-parallel 
reduction in activity resulting from the R303C mutation and in general ADSL-substrate 
interactions, ITC was performed on WT and R303C ADSL with their products AMP and 
AICAR. By measuring the amount of heat liberated per injection as a function of the 
molar ratio of the substrate and protein, thermodynamic parameters for R303C and WT 
ADSL’s interaction with their products were calculated (Table 4). Intriguingly, product 
binding does not show any evidence of cooperativity, as the data fit to an independent 
model rather than a multiple binding site model. This does not necessarily rule out the 
possibility that the substrate binding is cooperative, but suggests that cooperativity may 
require inclusion of interactions between the fumarate component of the substrates and 
ADSL, which is lacking in the products.  
Table 4: ITC Thermodynamic Parameters of ADSL 
  AMP AICAR 
  WT R303C WT R303C 
Kd (µM) 54 ± 3 130 ± 8 34 ± 2 121.9 ± 0.9 
ΔH (kJ*mol-1) -35 ± 2 -5.9 ± 0.2 -53 ± 1 -16.7 ± 0.5 
TΔS (kJ*mol-1) -12 ± 1 15.92 ± 0.06 -28 ± 1 5.3 ± 0.5 
ΔG (kJ*mol-1) -23.9 ± 0.1 -21.8 ± 0.2 -25.1 ± 0.1 -21.95 ± 0.02 
n 0.99 ± 0.01 1.01 ± 0.04 1.00 ± 0.02 1.00 ± 0.02 
Data sets were collected in duplicate and analyzed with NanoAnalyze software and fit to an 
independent model concurrently with a blank constant model to adjust for heat of dilution. All 
measurements were from 25 injections of 2.5 mM AMP into 170 µL protein in 25 mM HEPES, pH 
7.0, 150 mM KCl, 2 mM DTT at 20°C. 
 
Beyond the absence of cooperativity observed, the Kd values for WT ADSL were 
54 and 34 µM for AMP and AICAR, respectively (Table 3). The thermodynamic 
properties that are responsible for AICAR and AMP binding to WT ADSL globally are 
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similar with the enthalpic component, ΔH, being the predominant driving force and the 
entropic component, ΔS, being unfavorable. Although similar, the thermodynamic 
properties are not identical. AICAR binding liberates an additional 18 kJ/mol, suggesting 
an additional hydrogen bond may be formed between AICAR and WT ADSL that is 
absent in an AMP and WT ADSL complex. The lack of this additional enthalpic 
contribution is partially offset in the AMP and WT ADSL complex by the reduced 
unfavorable entropic component compared to the AICAR and WT ADSL complex. 
Overall, this leads to a difference in ΔG of AMP and AICAR to WT ADSL to be only 1.2 
kJ/mol in AICAR’s favor. 
Intriguingly, the R303C mutation impacts the ability of ADSL to form a complex 
with AMP and AICAR in two distinct manners. The enthalpic component for both 
products decreases by a similar degree of ~30 kJ/mol suggesting the loss of one to two 
hydrogen bonds, whose identity could be common between the two products and ADSL. 
Additionally, the R303C mutation shifts the ADSL complex formation with AMP and 
AICAR from an unfavorable to favorable entropic event. Taken together, these 
thermodynamic factors result in a similar decrease of ΔG and increases of 76 and 88 µM 
in the Kd of AMP and AICAR respectively. As a result, the R303C mutation appears to 
negatively affect ADSL’s interaction with AMP and AICAR almost indistinguishably. 
X-ray Structural Elucidation of R303C and WT ADSL 
Recently, a study proposed that the R303C mutation may distort the active site 
cleft (Zikánová et al. 2010). To investigate the structural effects of the R303C mutation 
on ADSL and how these effects might be linked to the lower activity and unique 
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specificity of ADSL with the R303C mutation, the crystal structure of R303C ADSL 
(R303C-ADSL) was elucidated to 2.60 Å. A homo-tetramer in the asymmetrical unit was 
observed, with each monomer composed of 16 α -helices and 3 small β -sheets, which 
can be further divided into three domains (Fig. 12, 13). Electron density was observed for 
the majority of all 5–476 ADSL residues in all monomers, with residues 5–112 forming 
domain 1, residues 113–364 as domain 2, and 364–476 as domain 3. A notable exception 
was the residue range 286–291 in all monomers. These residues comprise the β3-α10 
loop, also known as the C3 loop, which is located near ADSL’s active site and expected 
to contain an important catalytic serine, S289. The lack of density for this region is not 
fully unexpected, as it has been unobserved in all but one bacterial ADSL X-ray 
structure. As a result, the loop is suggested to be highly flexible. Apart from the expected 
differences in the positions of the residues just prior to and after the missing density of 
the β3-α10 loop, the only other notable difference observed between the four monomers 
of R303C-ADSL resides in domain 3 of the structure. This domain is on the periphery of 
the tetrameric complex likely resulting in the small alterations and higher B-factors 
between the four monomers in that region (Fig. 13).  
Despite these differences on the periphery of the protein, from a distance the 
R303C-ADSL globally resembles that of the PDB entry 2VD6 ADSL with its four active 
sites a mixture of active site bound SAMP, or AMP with fumarate (ADSL-SAMP) as 
well as AMP bound ADSL PDB entry 2J91 (ADSL-AMP). Unlike ADSL-AMP where 
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all of the active sites are indistinguishably bound to AMP, ADSL-SAMP has its active  
sites 1 and 2 filled with AMP and fumarate, while the SAMP was observed in active sites  
2 and 4 (Fig 14a,b). Both of these ligand bound structures previously have alluded to 
ADSL active sites being formed by three contributing monomers. For example, in the 
active site 1, the monophosphate group of AMP hydrogen bonds to three residues from 
chain A. The fumarate interacts with 3 residues from chain A bridging across to 
interactions with two residues from chain B, and one from chain D (Fig. 14a). 
Figure 12: Sequence alignment of ADSL from various species. ADSLs are from H. sapiens 
(GenBank AAC83935.1), M. musculus (GenBank AAB60684.1), B. subtilis (NCBI Reference 
Sequence: YP_003865018.1), and C. griseus (NCBI Reference Sequence: NP_001230974.1). 
Secondary structure of hADSL according to Defined Secondary Structure of Proteins (DSSP) is 
represented by green cylinders (helical regions), orange arrows (β-sheet regions), black lines (loops), 
and black dashes (unstructured regions). Mutation site 303 is marked with an asterisk. The location of 
helices α3 and α4 is highlighted with a red box. The C3 loop is enclosed in black brackets. Catalytic 
residues H159 and S289 are marked with blue asterisks. Domains 1, 2, and 3 are indicated with bars in 
shades of brown. 
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The ADSL-SAMP active sites with SAMP bound have similar intermonomeric 
interactions (Fig. 14b). Not surprisingly, upon inspection of the corresponding active site 
of R303C ADSL, density for the R303 side chain is largely absent with only enough 
remaining to represent a mutation to cysteine at that position (Fig. 14c). Based on the 
Figure 13: Side and Top view of WT homo-tetramer. P212121 asymmetric unit of WT crystal. 
Monomers A, B, C and D are rendered red, green, blue, and yellow, respectively. Domains 1-3 are 
indicated for Monomer C. Active sites are indicated with arrows. 
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ligand bound structures, this mutation would appear to simply eliminate the hydrogen 
bonds formed between the monophosphate in the AMP, or SAMP, and ADSL. This loss 
of the phosphate-R303 interaction, which also likely exists with AICAR, could be 
reflected in the enthalpy change detected by ITC for AMP and AICAR. However, upon 
closer examination by superimposing the active sites of R303C-ADSL with the 
corresponding sites in ADSL-SAMP revealed that the two structures’ corresponding 
active sites are not entirely identical, giving possible credence to an earlier study’s 
suggestion that the R303C mutation may disrupt the active site cleft (Zikánová et al. 
2010). Specifically, comparison of R303C-ADSL’s active sites with ADSL-SAMP’s 
corresponding fumarate and AMP bound active sites shows a 2.5 Å shift of α-helices 2, 3 
and 4 (Fig. 15a). This shift is also observed between R303-ADSL and ADSL-AMP. 
Interestingly similar, but not exact, shifts are also observed between R303C-ADSL’s 
active sites and the SAMP filled active sites of ADSL-SAMP. To determine if the shift in 
α-helices 2 – 4 was related to the R303C mutation or a conformational change related to 
substrate binding, the structure of WT ADSL in its apo form (WT-ADSL-apo) was 
elucidated to 2.70 Å (Fig. 15b). Similar to the ADSL-R303C and ADSL-SAMP, electron 
density for residues 283–293 (β3-α10 loop) was not observed. Similarly to R303C-
ADSL, WT-ADSL’s monomers were largely indistinguishable outside of the domain 3. 
Intriguingly, comparison of the WT-ADSL-apo with ADSL-SAMP revealed a 2.7 Å shift 
of α-helices 2 – 4 in line to those observed previously in the R303C-ADSL and ADSL-
SAMP comparison, indicating that substrate binding is likely the major cause of the shifts 
observed between the ADSL-R303C and the ADSL-SAMP (Fig. 15c), while comparison 
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Figure 14: Comparison of ADSL active sites for WT, WT with substrate, and R303C mutant. (a) 
Wall-eyed stereo view of an ADSL-SAMP active site with AMP and fumarate occupying the active 
site. AMP is rendered pink and fumarate is rendered tan. Heteroatoms are colored according to their 
element. Water molecules (grey) are depicted as spheres and are scaled to 50% for clarity. The 
monomer each residue belongs to is given in parentheses after the residue number. (b) Wall-eyed stereo 
view of an ADSL-SAMP active site with SAMP occupying the active site. SAMP is rendered purple, 
and heteroatoms and water molecules are as in (a). (c) Wall-eyed stereo view of R303C ADSL active 
site. Monomers A, B and D are rendered red, green, and yellow, respectively. Heteroatoms are colored 
according to their element. Water molecules (cyan) are depicted as spheres and are scaled to 50%, and 
the side chain of R85 is hidden for clarity.  
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Figure 15: Substrate induced α -helices 2, 3 and 4 shift. (a) Wall eyed stereo view comparing the 
mobile loop α2-α4 between ADSL-SAMP (grey) and R303C-ADSL. (b) Wall-eyed stereo view of WT 
active site colored salmon, light yellow and pale green, with waters colored aqua. Heteroatoms are 
colored according to their element. Water molecules are depicted as spheres and are scaled to 50%, and 
the side chain of R85 is hidden for clarity. The monomer each residue belongs to is given in parentheses 
after the residue number. (c) Wall eyed stereo view comparing the mobile loop α2-α4 between ADSL-
SAMP and WT ADSL.  Coloring is as in (a) and (b). (d) Wall eyed stereo view comparing the mobile 
loop α2-α4 between R303C and WT ADSL.  Coloring is as in (a) and (c). 
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of WTADSL-apo to R303C-ADSL revealed nearly identical structures (Fig. 15d). In 
addition, WTADSL-apo reveals an additional apo form of the ADSL active site that is 
divergent from product and substrate bound active sites previously observed.  
Modeling of AMP/AICAR and Fumarate Binding in the Active Site 
Currently, no crystal structure for WT ADSL with AICAR bound has been 
resolved. Utilizing the elucidated WT-ADSL-apo and ADSL-SAMP structures along 
with the understanding of local active site shifts within the active site upon substrate 
binding; AICAR and fumarate were modeled into the active site. Specifically, the AMP 
and fumarate bound active site of 2VD6 was employed as a template for the initial 
location of AICAR and fumarate within an active site of the WT-ADSL-apo. Using the 
Amber10 simulation package, by energy minimization the ADSL-AICAR-fumarate 
model structure was determined (Fig. 16a). To validate the modeling parameters used, we 
also energy minimized the structure with AMP and fumarate instead in the WT-ADSL-
apo active site. The resulting AMP and fumarate bound ADSL model was nearly 
identical to that of AMP and fumarate bound in ADSL-SAMP.  
As is evident from the figure, the placement of the fumarate, phosphate and ribose 
groups of AICAR and SAMP within the ADSL active site is similar (Fig. 16b). However, 
the remaining structure of the two substrates forms divergent interactions within the 
active site. This divergence could be a result of a rotatable bond between AICAR’s 
imidazole ring and carbonyl carbon, whereas the presence of the pyrimidine in AMP 
eliminates the ability of the corresponding bond to rotate (Toth and Yeates 2000). As a 
result, this flexibility in AICAR and an amine group substituent of its imidazole ring 
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potentially allows the amine to stick out in a space previously occupied by a water 
molecule potentially facilitating hydrogen bond with the hydroxyl group of the conserved 
S334 (Fig 12). Additionally, the rotation of the AICAR amide causes an alteration in the 
R329 side chain to form a hydrogen bond with AICAR’s amide group.  
Discussion 
Origins of ADSL Cooperativity 
The elucidation of the ADSL-SAMP structure has previously been suggested to 
support cooperativity in human ADSL, as AMP and fumarate are found in two active 
sites and with the other two occupied by SAMP. However, previously limited 
Figure 16: ADSL-AICAR-fumarate model. (a) Wall-eyed stereo view of model of WT active site 
with AICAR and fumarate occupying the active site. AICAR and fumarate are rendered yellow. 
Heteroatoms are colored according to their element. The monomer to which each residue belongs is 
given in parentheses after the residue number. (b) View of model of WT active site with AMP and 
fumarate overlaying model of WT active site with AICAR and fumarate. WT with AMP is rendered 
grey with AMP in pink and fumarate in tan, while WT with AICAR residues are teal with AICAR and 
fumarate in yellow. 
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biochemical data existed to support the origins or form of the cooperativity found in 
ADSL. Interestingly, the kinetic and thermodynamic properties of the WT ADSL and the 
R303C mutant suggest that the involvement of all three monomers that comprise an 
ADSL active site is necessary to achieve ADSL’s positive cooperativity. Specifically, no 
cooperativity was observed when binding AICAR, or AMP, to WT ADSL. Binding of 
these products form the majority of their interactions with only two of the monomers. For 
example, in active site 1, AMP interacts with six residues from monomer A, and one 
from monomer B. Additionally, the phosphate group of AMP is anchored with two 
additional residues from a relatively immobile portion of monomer D. (Fig. 14a). This 
leaves the fumarate product to span interactions between monomer A’s mobile α-helices 
2 – 4, monomer B, and the near β3-α10 catalytic loop region of monomer D, suggesting 
that it is necessary for cooperativity to be observed. In line with this hypothesis, mutation 
of R303 to cysteine, which removes two hydrogen bonds, thus removing the majority of 
the interactions between monomer D and SAMP, results in no cooperativity (Fig. 14b). 
Beyond the necessity for the substrate, or products, to involve all three monomers 
when binding to achieve an allosteric response, comparison of the WT-ADSL-apo and 
ADSL-SAMP active sites provided a glimpse into the model of allosteric regulation that 
ADSL undergoes. Specifically, the WT-ADSL-apo active sites are considerably more 
open to the bulk solvent then those of the ADSL-SAMP and ADSL-AMP structures (Fig. 
17a). The 2.7 Å shift of α-helices 2, 3 and 4 observed between the WT-ADSL-apo active 
sites and those bound with AMP, or AMP and fumarate, illustrates a clamping down of 
the active site over SAMP, or AMP. With AICAR and SAICAR having homologous 
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phosphate, fumarate, and ribose moieties to that of AMP, the same shift is likely to occur 
upon the binding of these ligands as well. This closure of the active site around SAMP 
suggests that a concerted model of allosteric regulation would not be possible (Fig. 17c). 
In other words, if this shift occurred in a neighboring active site as a result of binding 
SAMP and SAICAR for the reaction running in the forward direction, SAMP attempting 
to bind to the neighboring active site would be sterically impeded. This would not be 
reflective of the positive cooperativity observed. Applying sequential allosteric regulation 
to the reverse reaction is less certain. The binding of AMP and AICAR would also be 
sterically impeded from binding to an active site that already underwent a shift of α-
helices 2, 3 and 4. However, as illustrated by the thermodynamic information, the binding 
of AMP and AICAR is does not illustrate cooperativity. With fumarate binding at the top 
of the active site, which is exposed to the bulk solvent, a concerted model cannot be ruled 
out in the reverse direction (Fig. 16b).  
Beyond the sequential model of allosteric modulation of ADSL, in what order, or 
the extent to which the active sites fill with substrates remains an open question. The 
ADSL-SAMP structure has its two active sites on the same end of ADSL occupied by 
SAMP and other distal active sites bound with fumarate and AMP. The absence of 
SAMP in all of the active sites could be due to restraints of the enzyme imposed by the 
crystal lattice, but alternatively might propose that substrates bind to adjacent active sites 
first, or only can bind to them. The latter would infer that the active sites at one end of the 
ADSL tetramer communicate to its distal neighbors. Although the mild loss of 
cooperativity observed by Ariyananda et al. (2009) by an ADSL mutation L311V at the 
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center of the tetramer would support this possibility, additional structurally guided 
mutagenesis along monomer interfaces and molecular dynamics simulations will be 
required to completely tease out the global allosteric nature of ADSL. 
 
Catalytic Effects of R303C Mutation 
The loss of cooperativity because of the R303C mutation removal of hydrogen 
bonds with one of the three monomers comprising the active site as reflected in the 
structures of ADSL-SAMP, or ADSL-AMP, would not itself explain the divergent 
catalytic properties of ADSL observed towards SAICAR and SAMP. However, the 
combination of the kinetic and thermodynamic data coupled with the structural evidence 
suggests that the R303C mutation illuminates SAICAR as a better substrate for ADSL. At 
first glance, the unparallel reduction in kcat between SAMP and SAICAR upon the R303C 
mutation could suggest that the divergence in catalytic ability of ADSL between SAMP 
Figure 17: Constriction of the ADSL active site upon substrate binding. (a) Surface rendering of 
WT-ADSL-apo active site 1. WT active site depicted in salmon, light yellow and pale green 
corresponding to monomer A, B, and D respectively. R85 side chain is shown with transparency to 
reflect the lack of electron density for the side chain in all monomers. AMP and fumarate from active 
site 1 of ADSL-SAMP was placed in the apo active site for scaling purposes. (b) Surface rendering of 
SAMP and fumarate bound active site 1 of ADSL-SAMP. Coloring of light grey, medium grey, and 
dark grey correspond to monomers A, B, and D respectively.  (c) Surface rendering of SAMP and 
fumarate bound active site of ADSL-SAMP. Coloring of light grey, medium grey, and dark grey 
correspond to monomers A, D, and C respectively.  All waters were removed from surface renderings 
in (a-c). 
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and SAICAR is due to a lack of substrate binding that favors SAICAR, or AICAR 
binding over that of SAMP. However, the KM for SAICAR is slightly elevated relative to 
that of SAMP indicating that binding of SAICAR might be slightly weaker (Table 3). 
Moreover, the ADSL ligand bound structures have R303 forming hydrogen bonds to the 
phosphate group that is conserved between SAICAR and AICAR (Fig. 14). Also, the 
thermodynamic data reflects that the mutation causes a loss of enthalpy at almost equal 
magnitude for both AICAR and AMP, reflective of a loss of the same ADSL-phosphate 
group interactions. Despite the loss of the bond to the phosphate group, the overall ΔGbind 
for both products remains similar to WT ADSL. This is accomplished by shifting the 
product binding from an unfavorable to favorable entropic event. The resulting Kd’s for 
both substrates are nearly equally decreased by approximately 2.5–3 fold. This near equal 
drop in Kd but not kcat suggests that the R303C mutation is indirectly affecting the 
catalytic ability of ADSL divergently for its two substrates. In other words, this 
thermodynamic, kinetic, and structural evidence suggests that the substrate can bind to 
the active site at a significant affinity despite the R303C mutation. As a result, unlike WT 
ADSL, the R303C mutant is likely operating at rapid equilibrium state, where if the 
substrate binds to ADSL, most substrate will dissociate, and only a small amount will be 
converted to product. 
This would suggest that ADSL is more efficient at cleaving the fumarate-
AICAR/AMP bond of SAICAR than SAMP. The inequality of catalysis might suggest 
that SAICAR and SAMP do not follow the same mechanistic pathway. The reaction 
mechanism for conversion of SAMP and SAICAR by ADSL has been previously 
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described as a general acid-base mechanism resulting in β-elimination of fumarate (Fig. 
18) (Tsai et al. 2007). Although, the conversion of SAICAR to AICAR and fumarate 
could follow the same steps as the SAMP to AMP mechanism, due to the presence of an 
Figure 18: Proposed mechanism for SAICAR to AICAR plus fumarate and for SAMP to AMP 
plus fumarate. 
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additional carbonyl in SAICAR, there is another possibility. In this SAICAR selective 
pathway, the first two steps are the same: the Cβ-proton is removed, and the negative 
charge is stabilized by the δ-carboxyl group. However, in the third step, as the electron 
density from the double-negatively charge carboxyl group is shifted down and the Cα-N6 
bond is broken, a double bond is formed between N6 and the carbonyl carbon, and 
electron density is pushed up onto the carbonyl oxygen. Then, in the last step, this 
negative charge moves back down to form a C-O double bond as N6 becomes protonated 
by H159. This negatively charged oxygen may be stabilized by nearby positively charged 
residue, R235. This additional stabilization of the intermediate may be a factor in the 
faster reaction rate of SAICAR compared to SAMP. 
An alternative possibility, or potential additional factor, for the inequality of bond 
cleavage between SAMP and SAICAR is the ability of SAICAR to be positioned with the 
active site in a more catalytically effective orientation than SAMP. The loss of the 
hydrogen bonds that R303 contributed to substrate binding potentially affected the ability 
to orient SAMP and SAICAR ideally for cleavage. Unlike SAMP, which possess a 
pyrimidine ring, SAICAR has a single rotatable bond that has been previously suggested 
to infer greater flexibility to adopt different conformations (Toth and Yeates 2000). This 
also might explain the lack of unparallel reduction in catalytic ability of B. subtilis 
ADSL. In that case, B. subtilis ADSL has an arginine in place of human ADSL T354 that 
may provide a similar influence. Unfortunately in the Palenchar and Colman (2003) study 
that looked at B. subtilis ADSL corresponding human ADSL R303C mutation (B. subtilis 
ADSL N276C), only performed a double mutation to mimic the human active site 
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configuration and did not include a single mutation for the corresponding arginine at 
human ADSL’s T354. This prevented observing whether elimination of anchoring 
ADSL’s substrates by a third arginine resulted in unparallel catalytic ability. 
Additionally, the thermodynamic data suggests that AICAR forms an additional 
hydrogen bond not present in the ADSL-AMP complex. The enthalpic divergence 
between the two substrates remains after the introduction of the R303C mutation. The 
ability of SAICAR to possess an additional point of contact within the ADSL active site 
could ensure that SAICAR properly oriented within the active site more often then 
SAMP, contributing to the unparallel kcat between SAMP and SAICAR observed. Based 
on the ADSL-AICAR-fumarate model, the additional hydrogen bond could be reflective 
of an interaction between AICAR and the highly conserved S334 (Fig 16a). Curiously, 
even in human ADSL’s distant homolog of B. subtilis, this serine is conserved. This 
serine has not previously been implicated in substrate binding or catalysis, as it does not 
interact directly with SAMP or AMP within the ADSL-SAMP and ADSL-AMP 
structures. Naturally, additional site-directed mutagenesis efforts within the active site 
including S334, or an X-ray structure of ADSL with SAICAR, or AICAR, will be 
necessary to fully identify the ADSL residue acceptor that forms the additional hydrogen 
bond with AICAR and bring final clarity to the unparallel catalytic activity observed. 
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